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Abstract 
 
 
Male fertility is largely controlled by the hypothalamic-pituitary axis, a careful balance 
between stimulating and suppressing gene expression and the secretion of hormones. The 
critical factors for male fertility have in the past been thought to be limited to testosterone 
and the gonadotropins. Estrogen has only recently been demonstrated to be both a crucial 
requirement for fertility and a cause of infertility. Reports in the early 1990s demonstrated 
a decrease in mean sperm counts over the last 50 years. A hypothesis for this observation is 
the increase of xenoestrogens in the environment that are able to mimic and potential 
disrupt the natural estrogens involvement in fertility. Although the mechanisms of 
estrogens involvement are not yet defined, the Sertoli cells are a potential sites of action as 
they possess receptors for the hormone and are able to locally produce it. Sertoli cells both 
act to protect and provide for the male germ cells and the developing spermatozoa. 
Pyrethroids are common synthetic insecticides of which some have previously shown 
estrogenic activity. Therefore this investigation examined the effects of pyrethoids, whose 
estrogenicity was confirmed via the yeast assay, on the estrogen receptor expression in 
mouse Sertoli cells as a model for general effects of estrogenic chemicals on male fertility. 
The results first confirmed the estrogenicity of some pyrethroids and these pyrethroids 
when exposed to mouse Sertoli cells effected estrogen receptor mRNA expression however 
in a different way to the natural ligand 17β-estradiol.   
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1 Introduction 
 
Understanding the involvement of hormones in male fertility is crucial to the development 
of treatments for the growing number of sub-fertile men. The interaction of testosterone 
and the gonadotropins has been well documented but recently there has been a resurgence 
of interest in estrogens’ role as an important contributor to male fertility. Although 
generally associated with female fertility, estrogen is now recognised as both a requirement 
and a potential culprit in male fertility. Comprehensive research into estrogens’ 
involvement has been fuelled by the discovery of a second estrogen receptor (ERβ), and 
enabled by the development of knock-out mice models with targeted disruption of the ERα 
and ERβ genes. Interest has also been motivated by the suggestion that reduction in sperm 
counts and an increase in the incidence of testicular tumours in men in some industrialised 
areas may be due to estrogenic substances in the environment (Whorton et al., 1977, Stone 
et al., 1991, Swan et al., 2003, Bian et al., 2004, Xia et al., 2004). 
 
1.1 Link between sperm decline and increase presence of 
xenoestrogens in the environment 
 
Male causes account for up to 50% of infertility in couples and the rate of male infertility 
in developed countries increases by 0.5-1% every year (Swerdloff, 1985). Initial reports of 
a decline in semen quantity and quality by Carlsen et al., (1992) were met by fierce 
criticism due to the methodology employed. The meta-analysis undertaken by Carlsen et 
al., (1992) combined data sets from 61 studies that included over 14000 men with normal 
fertility with data dating back to 1930. Analysis showed a significant decrease in mean 
sperm count from 114 million/ml in 1940 to 66 million/ml in 1990 as well as a decrease 
inseminal volume. Criticism focused on the limitations of the meta-analysis and possible 
technical errors in the regression analysis. However re-evaluation of the data by a later 
study that in addition, included data up to 1996 confirmed the conclusions of the original 
study (Swan et al., 2000. 
 
An “estrogen” hypothesis was proposed by Sharpe and Skakkebaek (1993) for the 
observed decline in sperm number over the last 50 years. This hypothesis suggested that 
the increasing incidence of reproductive abnormalities in the human male may be related to 
increased oestrogen exposure in utero due to the increased concentration of estrogenic 
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chemicals in the environment. Hence subsequent efforts have been made to elucidate the 
direct involvement of estrogen in male infertility and whether other sources of estrogen 
such as xenoestrogens in the environment disrupt estrogens involvement.  
  
The term xenoestrogen refers to a group of endocrine disrupting chemicals (EDCs) with 
estrogenic activity. Xenoestrogens can induce estrogenic effects in multiple ways: they 
may act directly through estrogen receptors, or may disturb estrogen metabolism, thus 
increasing the levels of the endogenously produced ligand, 17β-estradiol. Numerous 
environmental chemicals, such as many organochlorine pesticides, PCBs, alkylphenol 
polyethoxylates, phthalates, and phytoestrogens are known to have estrogenic effects in 
vertebrates or in assays in vitro (reviewed in Topparri et al., 1996). Yet only a few of the 
tens of thousands of man-made chemicals have been tested for estrogenic or other 
endocrine activity. Pyrethroids are synthetic insecticides that are commonly used both in 
the home and in industry. The estrogenicity of a limited number of pyrethroids has been 
investigated by other authors however it has been noted that each pyrethroid compound is 
unique in its ability to influence several cellular pathways and based on evidence thus far, 
pyrethroids should be considered to be hormone disruptors although further investigations 
are required (Go et al., 1999). 
 
1.1.2 Localisation of Estrogen Receptors in the Male Reproductive 
Tissues 
 
The action of a hormone, such as estrogen, in a given tissue is substantiated by the 
identification of its specific receptor(s) in that tissue. Two estrogen receptor subtypes, ER 
(the classical ER) and ER (a recently discovered subtype), have been identified (Green et 
al., 1986, Kuiper et al., 1996). Recent investigations have demonstrated the differential 
expression of these subtypes in testes as well as the presence of additional transcript 
variants that differ between humans and rodents. ER has been reported to be strongly 
expressed in the efferent ductules however it has not been localized in testicular germ line 
or somatic cells of human or mouse testis. In contrast, ER immunostaining has been 
observed in spermatogonia, spermatocytes, and spermatids, as well as somatic cells (Couse 
et al., 1997, Denger et al., 2001).  
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1.1.3 Role of Estrogen and Estrogen Receptors in Male Infertility using 
Knockout-Mice Models  
 
The requirement of estrogen for normal spermatogenesis has been shown experimentally 
by targeted disruption of the aromatase gene in male mice models. ArKO mice lack an 
endogenous source of estrogen as the inactivation of the aromatase gene blocks estrogen 
biosynthesis by preventing the enzyme mediated conversion of testosterone to estradiol. 
ArKO mice exhibit late onset infertility with defects in round spermatids and increased 
apoptosis (Fisher et al., 1998, Robertson et al., 1999). Likewise the requirement for ER has 
been shown by knock-out mice models. ERKO mice are also infertile however the 
phenotype is different to the ArKO mice (Eddy et al., 1996). Testicular function has been 
shown to decline in male ERKO mice but as a secondary effect due to impaired function 
of the efferent ductules. ERKO mice on the other hand exhibit no obvious disturbances in 
testicular or epididymal function suggesting that ER is not essential to normal 
spermatogenesis (Ogawa et al., 1999). Not surprisingly then, the phenotype of mice with 
targeted disruption of both ER subtypes resembles ERKO mice (Krege et al., 1998). 
 
1.1.4 Evidence of Estrogens Regulating Germ Cell Development 
Mediated by ER   
 
The finding that ER is not a requirement for fertility in adult male mice according to the 
knockout models is unexpected considering that ER is the dominantly expressed ER 
subtype in both human and rodent testicular cells. There is considerable evidence in other 
tissues that a main role of ER is to moderate estrogen induce proliferation. The majority 
of evidence regarding the ER/ interaction relates to the decrease or loss of ER 
expression in estrogen dependent tumour progression (reviewed in Bardin et al., 2004). 
However recent evidence suggests a role of ER in moderating neonatal germ cell 
development in spermatogenesis (Delbes et al., 2004). This lends support to a universal 
role of ER in growth regulation of estrogen induced pathways.  
 
Inhibition of germ cell growth through an ER mediated process was shown 
experimentally where ER-/- mice showed 50% more germ cells compared to wild type 
mice, whereas no change in germ cell number was shown in ER-/- mice. The growth 
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inhibition by ER when activated occurred at endogenous concentrations of estrogen. In 
addition, approximately the same amount of inhibition was observed in mice heterozygous 
for ER-/+ who only express half as much ER protein (Delbes et al., 2004). These two 
factors illustrate that the inhibitory response of ER is highly sensitive to estrogen and 
does not require a large receptor occupancy level for the effect to be observed.  
 
The increase in germ cell numbers in the ER inactivated mice was essentially due to a 
lower rate of apoptosis and, to a lesser extent, to a higher rate of mitosis. Therefore the 
limiting of germ cell production via estrogen binding to ER may indicate ER’s 
involvement in activating apoptotic signalling pathways.  
 
1.1.5 Sertoli cells as Models for the Effects of Xenoestrogens on Male 
Infertility 
 
Among the cells that contain estrogen receptors and could mediate direct effects of 
estrogens within the testis are the Sertoli cells. Sertoli cells are the somatic cells of the 
testes that are essential for testis formation and spermatogenesis. Their location within the 
seminiferous tubules enables them to act as structural support to the spermatogonia as well 
as a physiological barrier which is thought to mediate hormone signals between the body 
and the testes (Setchell, 2004). Survival of germ cells has been shown to be proportional to 
that of the Sertoli cells. Experimental evidence of this relationship derives from three 
observations. Firstly, no situation exists in which germ cells have been observed in the 
absence of Sertoli cells (Griswold, 1998). Secondly, manipulating the number of Sertoli 
cells, by inhibiting their proliferation during testicular development, results in changes in 
testes size and spermatogenic output (Orth et al., (1988). Finally, the Sertoli cells express 
the receptors for gonadal steroids and exclusively possess the receptor for follicle 
stimulating hormone (FSH) involved in regulation of spermatogenesis (Zirkin et al., 1994). 
Two major mechanisms are thought to contribute to the relationship between the germ 
cells and Sertoli cells. Firstly, the tight junctions between Sertoli cells and germ cells and 
secondly the Sertoli cell involvement in the Fas mediated apoptotic signalling pathway. 
 
The tight junctions between the Sertoli cells and the germ cells are enabled by N-cadherin 
(N-cad). N-cad is a calcium dependent cell adhesion molecule that mediates cellular 
interactions. Both FSH and estradiol increase the mRNA expression of N-cad indicating an 
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estrogenic involvement in maintaining the junctions (MacCalman et al., 1997). 
Administration of an estrogen antagonist (tamoxifen) compromises structural integrity of 
the seminiferous epithelium and blocks spermatogenesis (Gill-Sharma et al., 1993). 
Likewise antibodies directed against N-cad inhibit Sertoli cell-germ cell interactions in 
vitro (Newton et al., 1993).  
 
Cell death in the testes occurs primarily, if not exclusively, via programmed cell death. 
Testicular apoptosis involves the Fas system. Sertoli cells produce Fas ligand (FasL), a 
proapoptotic factor that binds to Fas, a transmembrane receptor protein on germ cells. Thus 
the balance of prosurvival and proapoptotic signals originating from the Sertoli cells and 
associated changes in Fas protein in the germ cells are thought to control germ cell survival 
(Boekelheide et al., 2000). Estradiol treatment has been shown to inhibit apoptosis of germ 
cell in vitro. This effect was abolished by treatment with ER antagonist, ICI 182,780 
(Pentikainen et al., 2000) thus suggesting estradiols’ involvement of the Fas mediated 
apoptotic pathway possibly at the Sertoli cell level.  
 
1.1.6 Signal transduction mediated by estrogen receptors 
 
Estrogen receptor signalling is far from understood yet the complexity that has so far been 
resolved is extensive. Not only are the receptors able to form either homo or heterodimers 
if co-expressed but their transactivation ability is dependent on both the ligand bound, the 
recruitment of co-factor proteins, and even the chromatin structure of the DNA. The 
activation or inhibition of gene transcription induced by the estrogen receptors is also 
dependent on whether the ligand bound receptor binds to estrogen response elements 
(EREs) or activates through other protein recognition sites such as AP-1 and SP-1 
(reviewed in Mathews and Gustafsson, 2003). 
 
1.2 Pyrethroids 
 
In 1992 pyrethroid based insecticides contributed one fifth of the total insecticide 
application world wide. Since then use has continued to rise with pyrethroids employed in 
house hold fly sprays, carpet treatment and in a multitude of both commercial and 
domestic garden treatments.  
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Pyrethroids are synthetic derivatives of naturally occurring pyrethrins which are found in 
pyrethrum, the oleoresin extract of dried chrysanthemum flowers. As a consequence of 
being derived from a natural insecticide, insecticides containing pyrethroids have been 
referred to as “safe as chrysanthemum flowers.” However pyrethroids were developed to 
be more toxic with longer persistence times than the natural insecticide (reviewed by 
Khambay, 2002) and are often combined with other chemicals that increase their 
absorbance and compromise the human bodies’ ability to detoxify them. All of the 
pyrethroids investigated in this study are licensed for use in New Zealand (NZFSA, 2004) 
and are available in insecticide preparations for use in domestic gardening. 
 
The pyrethroid group is subdivided into two classes based on the different toxicological 
effects and symptoms, these subtypes also reflect a specific structural difference. (see 
Figure 1). Type I pyrethroids tend to produce milder poisoning symptoms whereas Type II 
Pyrethroids, which are identified by the presence of α-cyano group, lead to more severe 
poisoning symptoms (Ray, 2000, Raymond-Delpech et al., 2005). As insecticides 
pyrethrins and pyrethroids act as contact poisons; they rapidly penetrate via their highly 
lipophilic nature to disrupt the nervous system of insects. The primary targets of the 
insecticides are the sodium channels (reviewed in Raymond-Delpech et al., 2005). In 
addition Type II pyrethroids have been shown to also interfere with chlorine ion channels 
which increases their toxicity (Bradberry et al., 2005). Selectivity for insects, thus low 
mammalian toxicity, is a result of ion channel and metabolic enzyme differences as well as 
an approximate 10°C body temperature difference that negatively affects the pyrethroids 
potency in mammals. 
 
The two main metabolic mechanisms that degrade pyrethroids in biological systems are 
enzyme mediated oxidation and ester hydrolysis (Wollen et al., 1992, Leng et al., 1997, 
Choi et al., 2002, McCarthy et al., 2006). Understanding the metabolism of pyrethroids has 
enabled estimation of the physiological pyrethroid exposure levels based on metabolite 
levels in urine samples. By analysing the specific metabolites and their isomeric ratio 
present, both the type of pyrethroid and the route of absorption of the exposure can be 
determined (Wollen et al., 1992). Urine samples are preferable to blood or plasma samples 
as pyrethroids continue to degrade due to the presence of non-specific esterases in blood 
and plasma (Leng et al., 1997, Ramesh et al., 2004). 
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Figure 1 Chemical Structures of pyrethroids investigated in this work as well as pyrethrin I and 17-
estradiol. Pyrethoids are positioned according to their class determined by their physiological symptoms. 
The structure of the Permethrin metabolite included in the investigation is also given. 
 
 14 
Exposure to pyrethroids occurs through ingestion of the residual insecticide left on produce 
and through inhalation or dermal exposure during treatment. Absorbance is greatest 
through the gut (bioavailability 36%) and pulmonary membrane with absorbance through 
the skin less effective (1%) (Wollen et al., 1992). The physiological levels of pyrethroid 
exposure for both the general population and pesticide workers are detailed in the 
discussion (see section 4.2). Of significance is the consistent detection of pyrethroid 
metabolites in urine samples of the general population thus indicating widespread low level 
exposure. 
 
 
 
1.2.1 Pyrethroids as Xenoestrogens 
 
Structural similarities between pyrethroids and the natural estrogen 17-estradiol (refer to 
Figure 1) are not immediately apparent other than the presence of an aromatic ring. 
However, examination of both the end products and intermediate products of pyrethroid 
metabolism reveals structures which are suggested to have higher binding potential 
compared to their parent compounds based on essential binding characteristics of the 
estrogen receptor active site (McCarthy et al., 2006). These characteristics have been 
identified by structure-activity relationship analysis, enabled through competitive binding 
assays. Such investigations have been carried out for the last 40 years however advances in 
computer modelling technology has allowed more detailed analysis of a far more diverse 
set of structures. One such study (Fang et al., 2001) determined 5 clearly defined features 
that indicate a chemicals estrogenic potential. Firstly all chemicals so far found to be 
estrogenic contain a ring structure. As described in Fang et al., (2001) other structural 
features can contribute to this basic requirement namely; H-bond ability, precise O-O 
distance, rigid structure, steric moieties mimic 7 and 11-position and satisfactory 
hydrophobicity. Comparison of the permethrin metabolite investigated in this study with 
17-estradiol, illustrates three similarities that may contribute to the permethrin 
metabolites’ ability to bind to the estrogen receptors. The presence of a phenolic ring, 
electronegative hydroxyl groups on either end of the molecule for H-bonding and similar 
O-O distance in 2D (see Figure 2). 
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Figure 2 2D structural comparison of 17-estradiol and the permethrin metabolite (3-(4-
hydroxyphenoxy)benzyl alcohol) investigated in this study. Presence of phenolic ring in both structures is 
circled, arrows suggest similar O-O distance also present is the same electronegative groups on either end of 
the molecules. 
 
Metabolites are often supposed to be less toxic than their parent compounds as they result 
from what is primarily a detoxification process. However the possibility remains that the 
body may inadvertently transform already toxic or bio-active chemicals into even more 
potent metabolites. An example of metabolic activation in the body is the conversion of 
diadzein, found in soy products, to one of its major metabolites equol (7-hydroxyisoflavan) 
(Rowland et al., 2000). Equol has been found to be more estrogenic than its parent 
compound and thus the metabolism resulted in a more bio-active chemical (Rowland et al., 
1999, Markiewicz et al., 2000). The permethrin metabolite included in this work to 
investigate potential bio-activation of pyrethroids is an intermediate species in the 
permethrin degradation pathway (McCarthy et al., 2006).   
 
1.2.2 Are Xenoestrogens a Physiological Risk? 
 
An argument against the physiological effects of some xenoestrogens is that due to their 
low potency compared to 17β-estradiol the dose required to elicit an effect is well outside 
the physiological exposure range of these chemicals. This theory is heavily modelled on 
toxicology studies where the assumption is made that extrapolating from the high 
exposures levels tested is a valid risk assessment for predicting low doses effects in the 
physiological range. Evidence to the contrary has been presented for the xenoestrogens, 
bisphenol-A and nonylphenol and the phytoestrogen genistein (phytoestrogen refers to a 
naturally occurring xenoestrogen). The results were found to be consistent with a U-shaped 
dose response curve, thus effects were observed at low doses - even with doses below the 
established no effect level (Sheehan, 2000, Gupta, 2000, Kaiser, 2000). This highlights that 
effects at near toxic concentrations can be very dissimilar to effects at a physiological 
concentration and that the relationship is far from linear.  
O
OH
OH
CH
3
OH
OH
 16 
 
Low dose effects of xenoestrogens have been commented on by both the National Institute 
of Environmental Health/Environmental Protection Agency (NIEHS/EPA) and the World 
Health Organisation (WHO). Reports issued from these authorities, highlight the need for 
direct mechanistic evidence and therefore encourage further research into possible 
xenoestrogen effects especially at different life stages ((NIEHS, 2001, WHO, 2002a). Due 
to the difficulty of establishing causal associations between between low-level exposure 
(as found in the general public) and adverse human health effects the exact nature of the 
effect of xenoestrogens is yet to be determined (Safe, 2005). Thus it appears that direct 
mechanistic details need to be elucidated before potential health risk is verified by these 
authorities.   
 
Low potency chemicals may also have the potential to act in an additive or synergistic 
ways with either other xenoestrogens or in combination with estradiol. Additive effects 
have been demonstrated where xenoestrogens, combined at below their no-effect-
observed-concentrations, have been able to exhibit either an estrogenic response (Payne et 
al., 2000, Silva et al., 2002) or dramatically enhance 17β-estradiols’ hormone action 
(Rajapaksi et al., 2002).   
 
The comparative bioavailability of xeno-estrogens compared to the natural estrogen may 
also impact on their actual physiological potencies. Specific binding proteins, for example 
sex hormone binding globulin (SHBG) sequester 95% of circulating 17β-estradiol (Arnold 
et al., 1996). Circulating xenoestrogens are not sequestered by serum binding proteins to 
the same degree, due to lowered binding affinity therefore, their free concentration is 
proportionally higher. In addition lipophilicy of some xenoestrogens, for example 
nonylphenol, is higher than estradiol which increases the likelihood of bioaccumulation.  
 
Aside from directly perpetuating estrogenic pathways by binding to the receptors, 
xenoestrogens may also disrupt the normal hormone regulatory mechanisms eventuating in 
the same end product of endocrine disruption. Estrogens are rapidly metabolised in the 
testis e.g. by sulphotransferases after which they cannot bind to their receptors. If 
xenoestrogens, of which many mimic the structure of natural estrogen, are occupying the 
active sites of metabolic enzymes then this would extend the persistence time of natural 
estrogen perpetuating its effects (Toparri et al., 1996).  
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1.3 Aims of this Investigation 
 
The requirement of estrogen in male fertility has been established however, the 
mechanisms of this involvement are far from understood. There is concern that 
environmental estrogens may affect endogenous estrogens’ signalling pathways yet debate 
regarding the physiological consequences of this due to insufficient causal associations 
observed. 
 
The aims of this study were therefore to extend the current understanding of possible 
estrogenic responses occurring in the testes. To this end, examination of estrogen receptor 
levels in mouse Sertoli cells in response to treatment with both estradiol and xenoestrogens 
was investigated. The aspect of estrogen signalling relevant to this investigation is 
therefore the potential the effect of different ligands on the expression of ER and ER 
mRNA and possible implications this may have on spermatogenesis. 
 
The xenoestrogens of interest were commonly used pyrethroid compounds which have 
been detected in the general public. Initial screening of pyrethroids by the Yeast Estrogenic 
Assay thus aimed to indicate pyrethroids individual estrogenicity to enable selection of the 
most likely xenoestrogens for the mouse Sertoli cell exposure. Investigating the estrogen 
receptor levels as a result of the treatments aimed to determine if changes occurred and if 
so, whether this change was the same for pyrethroids as for the natural ER ligand 17β-
estradiol.   
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2.1 Materials and Methods 
 
2.1.1 Test Chemicals 
 
The commercial insecticides purchased contained the desired pyrethroids as their active 
ingredient. They are listed as follows, manufacturer, product name and concentration of 
active ingredient: 
M
cGregor’s Natural Insecticide, contained 7g/L Pyrethrins. 
Yates Ant & Spider Spray, contained 2.5g/L Permethrin. 
Defender Bug-B-Gon, contained 0.03g/L Bifenthrin. 
BASF Ripcord Plus, contained 15g/L α-Cypermethrin. 
Kiwicare NO Bugs Super, contained 10g/L Deltamethrin. 
Yates Mavrik, contained 9.6g/L Tau-fluvalinate. 
Bayer Rose and Bug Spray, contained 0.2g/L Cyfluthrin. 
Pure α-Cypermethrin was purchased from Sigma-Aldrich. 
The Permethrin metabolite, 3-(4-hydroxyphenoxy)benzyl alcohol was generously 
supplied by Anna M
c
Carthy who synthesised it as part of a PhD at University of 
Canterbury. The structure was confirmed by both 
1
H and 
13
C NMR and the chemical had a 
stock concentration of 40mg/L.  
 
2.2 Yeast Estrogen Screen  
 
The yeast assay screen was adapted from the method of Routledge and Sumpter (1996). 
The yeast used in this assay was purchased from the same source - Glaxo group. It had 
been transfected with the human estrogen receptor (ERα) gene into the main chromosome, 
and with expression plasmids. The expression plasmids contain estrogen responsive 
elements (ERE) and the lac-Z reporter gene encoding the enzyme β-galactosidase (β-gal). 
The yeast was incubated in medium containing specific test chemicals and the 
chromogenic substrate, chlorophenol red-β-D-galactopyranoside (CPRG). If the test 
chemicals were, or metabolised into, active ligands of ERα, the reporter gene lac-Z was 
expressed and β-gal produced and secreted into the medium which caused the CPRG 
(yellow) to be metabolised into a red product. The colour change measured by absorbance 
at 540 nm.  
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2.2.1 Preparation of Yeast Culture 
 
Preparation of the minimal and growth medium for the yeast assay was as per the method 
described by Routledge and Sumpter (1996). However preparation of the yeast differed 
from their protocol in that only 0.125 l of -20°C 10x concentrated yeast stock was used to 
inoculate the 24 hour culture. Also, from that 24 hour culture only 0.25 ml was added to 
assay medium compared to the suggested 2 ml. The lowered volumes of yeast used 
compared to the original paper reflects the faster growth rate of the yeast observed in this 
lab. The new yeast volumes were based on work by Thomson (2004), and by McCarthy et 
al., (2006) that established the yeast cultures from Glaxo group, used for this work. The 
fast growth of the yeast was likewise evident in this work where the yeasts’ optical density 
at 640 nm after 24 hour incubation was on average greater than 2.4, compared to a value of 
1.0 for the 24 hour culture reported by Routledge and Sumpter (1996). 
 
2.2.2 Assay Procedure 
 
The test chemicals were diluted with 96% v/v ethanol and 100 μl was aliquot into the first 
well and diluted across the remaining wells creating a 1:2 dilution gradient. After the serial 
dilution, 10 μl was transferred to a different row and left until the ethanol evaporated; 
subsequently 200 μl of assay medium was added. The assay medium consisted of growth 
medium plus 0.25 ml yeast (from the 24-hour culture OD value generally above 2.4) and 
0.5 ml CPRG per 45 mls of minimal media as described in Routledge and Sumpter (1996). 
A 17- estradiol standard was prepared in the same way and included on every plate as 
well as a blank containing only the assay medium. The plates were shaken in a fixed 
wavelength plate reader (BIO-TEK EL312) for 2 min prior to incubation at 32°C.  After 48 
hours incubation, the absorbance was measured at both 610 nm and 540 nm in the same 
plate reader.  
 
2.2.3 Data Analysis 
 
Absorbance at 540 nm was corrected for changes in turbidity caused by yeast growth by 
adjusting it by the difference between the optical density at 610 nm for wells with and 
without yeast. 
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Sample Corrected Absorbance at 540 nm = ODSample 540 nm - (ODSample 610 nm – ODBlank 610 nm)  
 
The corrected absorbance data was plotted using SigmaPlot 9.0 with the dose response 
curves fitted by either the Hills four parameter or Sigmoid four parameter equations. 
EC50 values were calculated by using the equation of the fitted line and the parameters 
given in Sigmaplot to find the concentration (x) which gave half maximal response, (y = 
min + ((max-min)/2)). 
Relative potency to estradiol was calculated by EC50 Estradiol /EC50 Chemical 
The absolute change in absorbance resulting from each treatment after the correction was 
assessed for significance using a paired-two-tailed Student’s t-test.  
 
2.3  TM4 Mouse Sertoli Cell Culture 
 
2.3.1 Cell Culture Protocol 
 
TM4 Mouse Sertoli cells from the American Type Culture Collection (ATCC catalogue 
number CRL-1715) were cultured in a phenol-red free medium containing a 1:1 mixture of 
Dulbecco’s Modified Eagles Medium and Ham’s F12 medium with 2.5 mM L- Glutamine 
containing 15 mM HEPES, 0.5 mM sodium pyruvate, and 1.2 g/L sodium bicarbonate and 
supplemented with 5% v/v horse serum and 2.5% v/v fetal bovine serum. Frozen vials 
stored at -80˚C were resuspended in T75 flasks with approximately 12 mls of media. 
Incubation was done in a 37°c humidity controlled incubator with 5% v/v CO2. 
 
Determination of doubling time was carried out by using the SRB assay (protocol below). 
Identical plates were set up each containing varied initial seeding densities estimated by 
manual cell counting. Manual cell counting was performed with the aid of trypan blue 
exclusion stain and a Makler counting chamber. Plates were then tested one per day for 
five days.   
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2.3.2 Quantitation of Cellular Protein in Cell Cultures 
 
2.3.2.1 Sulforhodamine B Colorimetric Assay (SRB assay) 
 
Skehan et al., (1990) developed the SRB assay for the in vitro measurement of cellular 
protein content in adherent and suspension cell cultures. The protocol involves fixation and 
subsequent staining where the SRB dye binds to the basic amino acids. Colorimetric 
analysis of the stained protein enables the estimation of cell number based on the 
proportionality of total protein to cell number. 
 
2.3.2.2 SRB General Protocol 
 
In a 96 well flat-bottom microplate, a final volume of 200 μl per well was added consisting 
of growth medium seeded with an appropriate cell density. After incubation for a minimum 
of 6 hours to allow attachment, 100 μl of 30% (w/v) trichloroacetic acid (TCA) was added 
to each well to a final concentration of 10% v/v, and left standing for 20 minutes at 4°C. 
TCA was removed by blotting on filter paper. The plate was gently washed with tap water 
and the washing was repeated 5 times. The fixed cells were then stained with 100 μl per 
well of 0.4% SRB in 1% v/v acetic acid and left standing for 20 minutes at room 
temperature. After staining the stain was removed and the cells were washed with 1% v/v 
acetic acid. After over night drying in a fume hood the stain was solubilised with 100 μl of 
10 mM Tris-base (Tris(hydroymethyl)methylamine), pH not adjusted. After solubilisation 
for 20 minutes, the plates were gently shaken for 30 seconds before the absorbance was 
measured at 540 nm on a fixed wavelength plate reader (BIO-TEK EL312). 
 
2.4 Sertoli Cell Pyrethroid Exposures 
 
Cypermethrin and Ripcord, the commercial product containing cypermethrin, were diluted 
in 96 % v/v ethanol to two final concentrations each of 36 M (3.6 x 10-5 M) and 0.36 nM 
(3.6 x 10
-10
 M). The permethrin metabolite was diluted to three concentrations, 69 M (6.9 
x 10
-5
 M), 0.69 nM (6.9 x 10
-10
 M) and 69 pM (6.9 x 10
-11
 M). 17-estradiol was also 
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diluted to two concentrations of 10 nM (1 x 10
-8
 M) and 0.3 nM (3 x 10
-10
 M). Each of 
these chemicals, at their specific concentrations, was applied to T25 flasks with three 
replicates per concentration. The same volume of ethanol was also applied to three other 
flasks to act as no treatment controls. The ethanol in all flasks was allowed to fully 
evaporate before the addition of the Sertoli cells. Bulk medium was made to contain 2 x 
10
4
 cells per ml and 4mls was added per flask giving final concentration of cells per flask 
at 8 x 10
4
. All flasks were incubated for approximately 100 hours before cells were 
harvested.   
 
2.5 RNA Extraction 
 
RNA was extracted from the exposed cells using an Invitrogen Micro-to-Midi Total RNA 
Purification System. The manufacturer’s protocol was followed but using the following 
options, where options were given. Harvested cells were frozen in either PBS or trypsin 
therefore prior to adding lysis solution they were pelleted at 2000 x g (max) for 5 mins 
straight from the -80 freezer. As advised by the protocol due to the number of cells, 0.6 ml 
of lysis solution was added to the cell pellet. Homogenisation was achieved by repeated 
drawing of the cells through a 21 gauge needle using a 5 ml syringe. One volume, 0.6 ml, 
of 70% v/v ethanol was added to each vial and the precipitate dispersed by pipetting. 
Spinning and the application of both wash buffer I and II were carried out as per the kit 
protocol. One aliquot of 30 μl of RNase-free water was used to recover RNA from the spin 
cartridge due to the low expected yield. 
 
2.5.1 RNA Quantification 
 
Extracted RNA from the exposed cells was quantified using the Quant-iT™ RNA Assay 
Kit *5-100ng* from Molecular Probes, Invitrogen and using a Stratagene MX3005P 
Quantitative PCR system to measure fluorescence. The Quant-iT ™ reagent bound to RNA 
has an excitation and emission maxima of 644 and 673 nm, respectively. The CY5 filter in 
the Stratagene system has excitation and emission wavelengths of 635 and 665 nm 
respectively. The reagent to buffer dilution was 1:100 and 10 μl of each standard was used. 
Using 10 μl of each Ecoli standard provided in the kit gave a standard curve of 5-100 ng 
against the corresponding fluorescence values. An R-squared value of >0.985 was 
suggested in the kit as acceptable and was achieved consistently with standard RNA 
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amounts up to 80 ng. To calculate the amount of RNA in the unknown sample per μl from 
the amount given off the standard curve, the volume read, volume diluted and dilution 
factor were accounted for.  
i.e : value off standard curve graph/volume read * dilution factor/volume diluted = ng/ μl 
 
2.2.5 DNase Treatment of Extracted RNA 
 
RNA samples were treated with DNase by adding 1 μl 10X buffer and 10X DNase I 
(Amplification Grade, Invitrogen) per volume of RNA. This was incubated at 25 ˚C for 15 
minutes then the reaction stopped by heating at 75 ˚C for 10 minutes, followed by 
immediate ice chilling. A no RT-PCR was performed for confirmation that no DNA 
contamination persisted. 
 
2.6 Two-step Quantitative RT-PCR 
2.6.1 First-Strand cDNA Synthesis 
 
First-strand cDNA synthesis from the DNase treated RNA was achieved by using 
Invitrogen SuperScript™ III Platinum® two step qRT-PCR kit. From the kit, 10 μl of 2x 
RT reaction mix was combined with 8 μl of the RNA sample to which 2 μl of enzyme mix, 
also from the kit, was added. Incubation times for the reaction were as per protocol 
supplied with the kit as well as the addition of RNase H. Fourteen of the RNA samples had 
relatively small amounts of RNA that were relatively dilute due to the extraction protocol. 
These samples were lyophilized and resuspended in autoclaved distilled water to enable a 
higher concentration of RNA in the 8 μl added to the cDNA reaction. 
 
2.6.2 Quantitative PCR 
 
After extensive optimisation, the following reaction conditions were used for the 
amplification of all cDNA samples. LUX
® 
primer sequences and expected product sizes 
are given in Table 1.  
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Each 25 μl reaction contained 2x Platinum® Quantitative PCR SuperMix-UDG, 50 nM of 
both the β-actin JOE labelled and the unlabelled primer, 50 nM of both the ER FAM 
labelled and the unlabelled primer, and 100 nM of both ERβ ALX546 labelled and the 
unlabelled primer. Reactions also included 50 nM of ROX reference dye and 5 μl cDNA 
and were made to 25 μl with autoclaved distilled water. The 5 μl of cDNA added per 
reaction contained the equivalence of 50 ng total RNA. No template controls contained 5 
μl of autoclaved distilled water in place of the cDNA. The cycling conditions were one 
cycle of 50˚C for 2 minutes and 95˚C for 2 minutes, then 45 cycles of 95˚C for 30 seconds 
and 60˚C for one minute. Fluorescence data was collected by endpoint data collection at 
the end of each cycle using HEX, CY3, FAM and ROX filters. The filters each detected 
the fluorescence caused by the Lux
®
 primers extension but only within their specific 
excitation and emission wavelengths. Hence CY3 filter detected the ALX546 label, HEX 
filter detected the JOE label and FAM filter detected the FAM label. ROX was measured 
as a passive reference dye to account for inaccuracies in reaction conditions such as small 
pipetting errors. The filter gain settings on the Stratagene Mx3005p employed were, x 1 for 
CY3(ER), x 8 FAM(ER) and x 2 JOE(-actin). 
 
The same reaction mix as described above for the quantitative PCR was also used for the 
no RT-PCR using DNase treated RNA in place of cDNA. 
 
Table 1 Lux Primer Details 
Gene Label Sequence Expected 
Fragment Size 
β-actin JOE CGGTTCTGAACCCTAAGGCCAAC[JOE]G 
109 
β-actin - CCAGAGGCATACAGGGACAGC 
ERα FAM CGGCGGAGACTCGCTACTGTGC[FAM]G 
144 
ERα - GGTGCATTGGTTTGTAGCTGGA 
ERβ ALX546 CGGCCTTCCTCCTATGTAGAGAGC[ALX546]G 
89 
ERβ - GGTGCTGCTGGGAACACTATA 
 
2.6.3 Post Amplification Data Analysis 
 
The amplification curves produced by the fluorescence data were adjusted by altering the 
analysis term settings in the Stratagene software. The default setting of adaptive baseline 
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was changed to non-adaptive baseline and the baseline manually set between 3-15 cycles. 
Threshold cycle was not altered and hence was calculated by the default set algorithm.  
The amplification of the -actin gene was an internal control used to normalise the 
amplifications of ER alpha and beta against variations in the template amount.  
 
 
 
Figure 3 Example of the data levels contributing to the analysis of each treatment. Treatment 1 
represents any of the treatments including the non-treated cells. Each treatment included three biological 
replicate cultures. The cDNA reversed transcribed from the RNA extracted from each culture was assayed in 
three separate PCR experiments. Within each PCR experiments three analytical replicas per culture sample 
were included. 
 
 
The set up of the experiment was such that the raw data required specific averaging of 
technical, analytical and biological replicas to gather average treatment results. For each 
treatment three replica cultures were set up (see Figure 3). Each culture contained 
approximately the same initial cell number. Three separate PCR assays were performed 
using cDNA reverse transcribed from the RNA of each culture. Within each technical 
replicate experiment, triplicate analytical replicates were assayed. The data from each 
culture i.e. the individual culture results, constitutes the average of three separate PCR 
reactions; this average is plotted on Figure 15. The data from each treatment, Figure 3, 
compiles of the average of the cultures for that treatment and is graphed on Figure 16. 
 
The relative expression fold-change of ER and ER was calculated based on the 
mathematical model presented by Pfaffl (2001). The equation encompasses the correction 
for changes in the control samples, accounting for reaction efficiencies and normalisation 
with the -actin expression. Gene of interest, (GOI) refers to either ER or ER and the 
PCR Experiment 1 
 PCR Experiment 2 
 PCR Experiment 3 
 
Biological 
Replicas 
 
Technical 
Replicas 
 
Analytical 
Replicas 
 
Treatment 
1 
 
Culture 1 
 
Culture 2 
 
Culture 3 
 
1 
2 
3 
 26 
normaliser gene (NORM) to -actin. Individual efficiency of the primer sets in the 
multiplex was calculated by construction of a standard curve of template concentrations. 
The resultant fold-changes were compared to the changes in the non-treated control and 
tested for significance by a paired-two-tailed Student’s t-test. 
 
Fold Change = Eff(GOI)
 (Ct GOI)
/ Eff(NORM)
  (Ct NORM)
 
Ct GOI = Ct(GOI) control
 – Ct(GOI) treated 
Ct NORM = Ct(NORM) control
 – Ct(NORM) treated 
 
The ratio of ER to ER expression was calculated by dividing the fold-change of ER by 
the fold-change of ER. Whether this ratio increased or decreased significantly from that 
of the non treated control was tested by a paired-two-tailed Student’s t-test. 
 
2.6.4 Gel Electrophoresis of PCR Products 
 
Amplification products were run on pre-made 4% agarose gels (E-Gel, Invitrogen) that 
separate 20 – 500bp DNA fragments. Wells were filled with either 20 μl of sample or 20 μl 
of 100bp DNA ladder (Invitrogen). Running time and voltage settings were as per protocol 
supplied with the E-Gel. 
 
 
 
 
 
 
 
 
3 Results 
3.1 Estrogenicity using the yeast assay 
The estrogenicity of the pyrethroids of interest was investigated using an in vitro yeast 
assay, with a representative set of results for the dosage based effects shown in Figure 4. 
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The concentrations of the chemicals were serially diluted with the highest concentration on 
the left of the figure. The specific concentration ranges of each chemical used in the assay 
are shown in the box at the end of each row. This figure illustrates the yellow background 
colour of the medium (row K in Figure 4) where there was no estrogenic response and the 
colour change to red when there was a positive estrogenic response (for example see row 
A). The presence or absence of a colour change was quantified by measuring the 
absorbance of the culture medium. The plates were read at 540 nm for the red colour 
development and 610 nm to account for the turbidity of the yeast growth. Absorbance data, 
corrected for the yeast growth are shown in Figure 5A-I. Some of the colour changes are 
visually detectable, but are statistically insignificant when graphed ( Figure 4, Figure 5).  
 
A  
17- Estradiol 
[10 - 0.005nM] 
B  
Permethrin 
Metabolite 
[925 – 0.45 M] 
C  
Cypermethrin 
[360 – 0.18 M] 
D  
Bifenthrin 
[3.5 – 0.002 M] 
E  
Cyfluthrin 
[23 – 0.01 M] 
F  
Permethrin 
[38 – 0.02 M] 
G  
Pyrethrin 
[65 – 0.03 M] 
H  
Ripcord 
(Cypermethrin) 
[360 – 0.18 M] 
I  
Deltamethrin 
[30 – 0.01 M] 
J  
Taufluvalinate 
[29 – 0.001 M] 
K  
Blank – Ethanol 
control 
 
 
Figure 4 A-K. Representative photos of the colour change response of the yeast growth medium to test 
compounds. Serial dilutions run left to right. Chemical name and concentration ranges are indicated to the 
right of each row. 
The yeast assay successfully identified 17-estradiol as estrogenic by its positive colour 
change and the response also displayed the expected dose based effect with the colour 
change most extreme at the highest concentration (see Figure 4, Row A). The permethrin 
metabolite and pure cypermethrin in rows B and C, respectively, show strong positive 
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responses over a wide concentration range. Bifenthrin also showed a positive colour 
change for most concentrations. The lack of colour change in the first well of the bifenthrin 
dilution (Row D) is an example of a false negative. This well appears yellow and quite 
clear but this was due to the yeast dying rather than a lack of response. The results for 
cyfluthrin show it was able to elicit an estrogenic response but within a narrow 
concentration range (see Figure 4, Row E). The lack of colour change seen at the higher 
concentrations of cyfluthrin in row C was thought to result from toxicity, similar to that 
seen at the highest concentration of bifenthrin in row D. A weak colour change at the high 
end of the concentration ranges tested was shown in rows F, G and H whereas no colour 
change was shown in rows I and J thus mirroring the control in which only ethanol was 
added (Row K). 
 
As outlined in the methods section, corrected absorbance at 540 nm was used in the 
analysis of the yeast assay data. Each of the pyrethroid chemicals were graphed according 
to the concentration ranges in which they were assessed, along with 17 - estradiol (Figure 
5, A-I). Estradiol served as both a positive control and bench mark to highlight the 
differences in the concentration ranges tested. The error bars represent the standard error 
and illustrate the variation between the replicate assays for each chemical. The curves were 
plotted using the program Sigmaplot and regression lines calculated by either the Hills 4 
parameter test (for the estradiol data) or Sigmoid 4 parameter test (the other chemicals). 
For both bifenthrin and cyfluthrin, the wells at the high end of their concentration ranges 
were excluded from the graphs because the lack of a response was the result of toxic 
effects of the chemicals.  
 
The estradiol data depicted on every graph showed the expected increase in absorbance 
with increase in concentration for a positive estrogenic chemical. This dose based response 
can be predicted by the equation of the sigmoid regression line fitted. The R-squared value 
shown on individual graphs indicates the robustness of the fitted regression line with a 
value of 1.0 representing a perfect fit. Thus, it specifies whether the equation of the line is 
a good representation of the data with accurate predictive power. 
 
The permethrin metabolite and the pure cypermethrin (Figures 5A and 5B respectively) 
induced the strongest response next to that of estradiol. These responses also displayed the 
best R-squared values for fit with their respective regression lines. This signifies that their 
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responses followed the non-linear sigmoidal shaped curve well and that the equation of the 
fitted line could be used to predict either absorbance or concentration with accuracy. 
 
 
For the bifenthrin graph (Figure 5C), the value for the well with the highest concentration 
was excluded because the toxic effect of bifenthrin killed all the yeast cells (see Figure 4, 
Row D). Dead and non-responsive yeast were differentiated by the cloudiness of the 
culture medium by measuring absorbance at 610 nm as yeast growth increased the 
turbidity and hence the optical density of the culture medium. The absorbance 
measurements for bifenthrin at the lower concentrations were very consistent as indicated 
by the very small error bars. The response appears to saturate at a much lower absorbance 
level compared to estradiol which may be an indicate the beginnings of toxicity. 
 
At high concentrations cyfluthrin also caused cell death. Thus the data from concentrations 
above 0.18 M where the colour change disappeared were removed and the remaining data 
from lower concentrations are shown on Figure 5D. The dose response of cyfluthrin 
appears almost linear, due in part to the very limited number of data points available at 
concentrations that were not affected by toxicity. This also means that the EC50 calculated 
for cyfluthrin (Table 2) is only tentative as the maximum response could not be achieved in 
the assay due to toxicity. 
 
Pyrethrin and Permethrin (Figures 5E and 5F) show relatively good R-squared values 
despite the sigmoidal curve appearing flat compared to that of estradiol. Colour change can 
be visually detected, although much weaker than that of estradiol (Figure 4). 
 
The lack of colour change for taufluvalinate and deltamethrin (see Figure 4, rows J and I) 
resulted in effectively flat lines and hence relatively low R-squared values (see Figure 5G 
and H respectively).  
 
Ripcord, a commercial product containing cypermethrin, showed no obvious change in 
absorbance over the concentration range tested (Figure 5I). However, the error for the 
higher concentrations was large, which could be masking the small colour change observed 
in Figure 4, Row H. 
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Figure 5 A-I. Dose response curves of all chemicals 
examined by the yeast assay. R-squared values of 
fitted regression lines are given in respective legends.  
 
 
The estrogenic response that was detected visually, EC50 values, the relative potency and 
significance level of each chemical tested are shown in Table 2. The EC50 values were 
determined from the regression lines where the EC50 was the concentration at which half 
the maximum absorbance was observed. The lower the concentration of the EC50 value, the 
more potent the chemical was found to be in that specific assay. Significance was 
calculated by a paired-two-tailed Student’s t-test, which compared the absorbance at the 
highest and at the lowest concentrations tested for each chemical. In the case of bifenthrin 
and cyfluthrin, where data at some concentrations were removed, the absorbance at the 
highest and lowest remaining concentrations was compared to test for a significant change.  
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Table 2 Summary of the responses of the chemicals assessed by the yeast estrogen screen. 
 
Chemical Response
 
EC50 (M)
 
 Relative Potency to 
17-Estradiol  
Significance 
level 

 
17-Estradiol + 1.5 x10
-10
 1 P << 0.00005 
Cyfluthrin +   NS 
Taufluvalinate -   NS 
Permethrin + 3.6 x 10
-6
 4.1 x 10
-5
 NS 
Permethrin Metabolite + 5.7 x 10
-6 
2.6 x 10
-5
 P < 0.001 
Bifenthrin + 4.5 x 10
-7
 3.3 x 10
-4
 P < 0.06 
Pyrethrin + 1.5 x 10
-5
 9.9 x 10
-6
 NS 
Deltamethrin -   NS 
Cypermethrin + 4.8 x 10
-5
 3.1 x 10
-6
 P < 0.05 
Ripcord (cypermethrin) + 1.6 x 10
-5
 9.4 x 10
-6
 NS 

Response based on colour change. 

EC50 was calculated from the regression lines of the absorbance 
data. 

Relative potency was calculated by the ratio between the estradiol EC50 and the EC50 of each 
other chemical 

Significance was calculated by a paired-two-tailed Student’s t-test comparing the 
change in absorbance. NS indicates non significant p values.  
 
Only deltamethrin and taufluvalinate showed no estrogenic response over their respective 
concentration ranges assessed. However, although a positive response was visually 
detectable in the rows containing permethrin, cyfluthrin and pyrethrin assays, the changes 
were not statistically significant. 
 
Of the pyrethroid chemicals that showed a statistically significant estrogenic response, all 
were much less estrogenic than estradiol. Relative potencies of 10
-4
,
 
10
-5
 and 10
-6
 were 
determined for bifenthrin, permethrin metabolite and cypermethrin respectively. 
 
3.2 Cell Culture of Sertoli Cells  
 
The Sulforhodamine B colorimetric assay was used as a fast and simple estimate of cell 
numbers through total protein measurement. The SRB dye binds to the basic amino acids 
which after removal of the unbound dye can be quantified by the absorbance at 540 nm. 
The SRB assay was established by Skehan et al., (1990) and has been validated by its 
routine use as part of the E-SCREEN assay (Soto et al., 1995). A five day growth 
experiment was used to chart the growth of mouse Sertoli cells from varying initial seeding 
densities (see Figure 6). The highest initial cell density, approximately 4.8 x10
5
/well, was 
estimated by manual cell counting, subsequent cell numbers were estimates based on the 
dilution of the cells in the first well. The absorbance data at 540 nm was used to plot 
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growth curves for five of the different seeding densities over the five day incubation period 
(see Figure 7).  
Dilution Series 
    High     Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Photographs showing the amount of stained protein according to the number of days 
incubated. Highest initial cell density per well is on the left (4.8 x10
5
) with a serial 1:2 dilution towards the 
right (2.3 x10
2
). Inside the black box are the dilutions (3.0 x10
4 
- 1.8 x10
3
) whose measurements were used to 
plot Figure 7. 
 
The progressive increase of staining in each well over the 5 days indicates an increase in 
protein, hence growth of the Sertoli cells. The highest initial cell density on the left of the 
Figure 6, stained strongly from Day 0 and the colour intensity approached the upper level 
of spectroscopic discrimination. The wells within the black box had little or no staining 
initially and progressed to mostly full colour. These wells within the black box are graphed 
in Figure 7. The detection range of the SRB assay is also demonstrated by the staining 
patterns on Figure 6. All wells had at least 200 cells initially, however many to the right of 
the black box did not show any visible staining on Day 0 or until after Day 2. 
DAY 0 
DAY 1 
DAY 2 
DAY 3 
DAY 4 
 
DAY 5 
 
3.0 x10
4
 
Cells 
1.8 x10
3
 
Cells 
2.3 x10
2
 
Cells 
4.8 x10
5 
    Cells 
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Figure 7 Growth of TM4 mouse Sertoli cells over five days measured by absorbance at 540 nm (± SE, 
n=3) after fixing and staining using SRB reagent. Legend indicates the initial approximate cell seeding 
densities calculated from the original cell count and the serial dilution factor.  
 
The TM4 mouse Sertoli cells exhibited normal growth characteristics of a lag phase and 
log growth phase (see Figure 7). As space and nutrients became a limiting factor, a slight 
decline or plateau was observed as reflected in the growth curve of the cells seeded at 
30000 cells per well. The R-squared value for the curve corresponding to the initial cell 
density of 30000 was the lowest at 0.987 whereas the other curves scored over 0.997. The 
measurement of Day 0 was taken after an initial 6 hours attachment time. This was 
required to prevent the cells from being lost during the fixing and staining process. The lag 
phase lasted for between two and four days; the exponential growth phase appeared around 
Day 2 and Day 4, depending on the initial seeding density. 
 
3.3 Exposure of Mouse Sertoli cells to pyrethroid chemicals 
 
The exposure to test chemicals of mouse Sertoli cells involved multiple treatments 
consisting of four different chemicals at multiple concentrations and a non-treated control. 
Each exposure experiment was carried out in T25 flasks in triplicates over an 
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approximately 100 hours of incubation. Photographs of the cell cultures were taken 
throughout the incubation period to assess changes in gross morphology and to estimate 
cell death. The increase in cell numbers over the three days for both the non-treated cells 
and the 36 M cypermethrin treatment are shown in Figure 8. The approximate confluence 
of the cells on Day 3 are shown for the other treatments (see Figure 9). Confluence was 
used as a cell density estimate, referring to the coverage of the flasks’ surface by the cells. 
 
  
  
  
  
Figure 8 Sertoli cell growth over the exposure period.  A,B,and C Non treated cells, Day 1,2 and 3 
respectively. D,E and F Cypermethrin treatment at 36 M, Day 1,2 and 3 respectively. Scale (nm).   
 
 
 
A D 
C 
B E 
F 
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Figure 9 Sertoli cell growth on Day 3 of the exposure period. Treatments A and B, 17-estradiol at 0.3 
nM and 10 nM respectively. C and D Ripcord (cypermethrin) at 0.36 nM and 36 M respectively. E, and F 
Permethrin metabolite at 0.69 nM and 69 M respectively. G and H cypermethrin at 0.36 nM and 36 M 
respectively. Scale (nm). 
 
The cells exposed to the cypermethrin treatment at 36 M showed similar growth 
progression as the non-treated cells over the three days (see Figure 8). This suggests the 
cypermethrin at that concentration did not cause increased toxicity relative to the non-
treated cells. Other treatments did result in either growth inhibition or increased toxicity 
and therefore showed a decrease in cell density at day three (see Figure 9). In particular the 
B 
D 
 G 
 E F 
H 
C 
A 
 37 
culture treated with the metabolite of permethrin at 69 M, resulted in very few cells that 
were sparsely distributed (see Figure 9F). The culture treated with the lower concentration 
of the permethrin metabolite was also less dense than the control (see Figure 9E). Ripcord 
(cypermethrin) at both concentrations lowered the final confluence of cells (Figure 9C and 
D), however not to the same degree as the permethrin metabolite treatment. The higher 
concentrations of both the estradiol treated flasks (Figure 9B) and the cypermethrin treated 
flasks (Figure 9H) showed more cells compared to the low concentrations (Figures 9A and 
G) and even relative to the control cultures (Figure 8C). It should be pointed out that the 
cells were not uniformly distributed over the surface of the flasks, hence, the photos are 
only used to demonstrate a representative section of a culture in a particular treatment.  
 
3.4 Quantification of Extracted RNA  
 
Quantification of the extracted RNA was required to enable approximately equal amounts 
of cDNA, reverse transcribed from the RNA, to be added to the each quantitative PCR 
reaction. Quantification of the extracted RNA from the exposed cells was performed by 
measuring the absorbance of the Quant-iT ™ reagent, a dye that fluoresces when bound to 
single-stranded RNA. Dilution of the extracted RNA samples was required to limit the 
fluorescence to within the linear portion of the standard curve. Due to the instability of the 
dyes’ fluorescence over time and when exposed to light, the standard curves were repeated 
for each run. The standard curve was consistently linear between runs for up to 80 ng of 
RNA (Figure 10). After calculation to adjust for the dilution and the amount read, final 
quantification results for each extraction are graphed on Figure 11. The RNA 
concentrations of the replicate cultures were not averaged as each sample was used 
individually in qRT-PCR. 
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Figure 10 Standard curve of RNA quantities by fluorescence detected using the CY5 filter on 
Stratagene Mx3005p. Each data point represents the average of triplicate samples. Unknowns were diluted 
to within a range of up to 80 ng/well. Unknown samples are indicated by triangles which represent the 
average of duplicate reactions.  
 
Generally the different cultures of the same treatment yielded approximately the equal 
concentrations of RNA (Figure 11). The RNA concentrations form replicate cultures were 
not averaged as each sample was independently amplified by real time RT-PCR. The large 
variation in the different treatments reflects both the amount of cells that were present at 
the time of harvest and their growth phase, hence, their transcriptional activity.  
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Figure 11 Concentration of RNA in ng/l obtained from Sertoli cell cultures exposed to various treatments. Each bar represents a separate culture with all treatments having 
three replicate cultures. Abbreviations; Met – Permethrin Metabolite, Cyper – Cypermethrin, E2 – 17-Estradiol, R.C – Ripcord. 
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3.51 Real-time multiplex RT-PCR of the Estrogen receptors 
 
Real-time multiplex reverse transcriptase polymerase chain reaction was used to amplify 
three target sequences, ER, ER and -actin. The estrogen receptors were the target 
genes with -actin acting as a normalising gene. LUX® primers with different fluorescent 
labels on one of each of the primer pairs enabled the amplification to be detected and 
graphed in real time by the Stratagene Mx3005p software. The cycle thresholds (Ct 
values) were used to calculate the relative expression of each target gene. Extensive 
optimisation was carried out to allow the fluorescence of all primers to be detected below 
the filter saturation levels and to minimise background noise. 
 
The optimisation of the multiplex reaction included alteration of LUX
® 
primer 
concentrations, template concentration, and adjustments of the filter gain settings on the 
Stratagene MX3005P. Increasing specific reaction mix components such as magnesium 
and dNTP concentrations was investigated but did not improve reaction efficiency for all 
primer pairs. 
 
The reaction efficiency when less than 100%, increases the number of amplification cycles 
required to reach the cycle threshold. Hence, the efficiency of each primer set in the 
multiplex reaction was calculated by construction of a standard curve using a dilution 
series of cDNA template quantities (Figure 12) and adjusted for in the equation employed 
to calculate the relative expression levels. Dissociation curves and agarose gels were also 
performed to investigate the presence of non-specific products which can adversely affect 
reaction efficiency and distort the actual gene expression levels detected (see Figures 13 
and 14).  
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Figure 12 Efficiency of each primer set in 
the multiplex real time PCR. Construction 
of the standard curve was enabled by a 
dilution series of cDNA template and their 
respective Ct values. Each point on the 
standard curves is the average of triplicate 
reactions. Legend shows individual 
efficiencies, the equation of each line and 
their respective R-Squared values. 
The efficiency of the amplification of 
ER and ER genes under the multiplex reaction conditions, outlined in the methods 
section, were found to be similar, 75.4% and 74.1% respectively (Figure 12). The 
efficiency of the -actin PCR is slightly higher but as this gene acts to normalize the other 
Ct values, both values will have the same adjustment thus not altering relative amounts.  
 
The standard curves of all three primer pairs shown in Figure 12 also illustrates that even 
over multiple dilutions the expression of the three genes do not overlap. The range of raw 
Ct values for -actin illustrate that -actin had the highest expression levels compared to 
the other target genes as indicated by the lowest range of Ct values approximately 18-22. 
ER gave Ct values between 26 and 30 over the dilution range and ER showed the 
lowest expression with raw Ct values between 34 and 38. 
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Figure 13 Disassociation curve for one run of the multiplex reactions of all samples and no-template 
controls. Each peak represents the specific disassociation of the products of one primer set indicated by 
labels.  
 
 
 
 
 
 
 
Figure 14 4% agarose gel of RT-PCR products from Singleplex,Duplex and Triplex assays as well as 
No Template  Controls. A Lane 1 10 l 100bp ladder. Lane 2 20 l ER and -actin duplex, Lane 3 20 l 
-actin and ER duplex. Lane 4 20 l ER, ER, -actin multiplex. Lane 5 20 l -actin singleplex. Lane 6 
20 l ER singleplex. Lane 7 20 l ER singleplex.  Lane 8 10 l of ER and -actin duplex, Lane 9 10 l 
of -actin and ER duplex. Lane 10 10 l of ER, ER, -actin multiplex. Lane 11 empty. Lane 12 20 l 
100bp ladder. B Lane 1 10 l 100bp ladder, Lane 2-9 No template control replicates. Lane 10 20 l 100bp 
ladder.  Lane 11 and 12 20 l ER, ER, -actin multiplex. 
  
Both the disassociation curves and the agarose gel analysis show that the multiplex 
reaction was successful in amplifying the three target sequences without non-specific 
products. The products visualised on the agarose gel are of the expected relative sizes with 
JOE (-actin)  
CY3 (ER-)  
FAM (ER-) 
B 
A B 
ER -144bp 
-actin - 109bp 
ER - 89bp 
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ER  migrating the furthest followed closely by -actin and the ER  band after a slightly 
larger gap (see Figure 14). Only three peaks are present on the disassociation curve 
indicating no non-specific product formation (Figure 13). The height of the peaks is 
related to the fluorescence of the primer label and not to the amount of product formed. 
 
3.6 Analysis of ER and ER expression  
 
Expression fold-change shows the relative expression of both ER and ER as a result of 
the specific treatments compared to their expression in the non-treated cells. Thus it is the 
amount the expression increases or decreases compared to the non-treated cultures 
arbitrarily given the expression value of one for both genes.   
 
The three biological replicates of two treatments, 69 M permethrin metabolite and 0.36 
nM cypermethrin, were unable to be consistently amplified due to low RNA yield. These 
treatments are therefore not included in the real time RT-PCR results. 
 
3.6.1 Individual Culture Results 
 
The fold-change data was averaged between separate PCR experiments for each individual 
culture (see Figure 15). Each PCR experiment contained triplicate samples from each 
individual culture. Thus the error bars represent the standard error of the mean between 
the PCR experiments, where the mean represents the average of the triplicates within each 
PCR experiment. 
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Figure 15 Average fold-change of ER alpha and ER beta mRNA expression over three PCR runs per 
replicate culture (± SEM, n=3). The cDNA from each culture was assayed in three separate PCR 
experiments with triplicate culture samples.  Abbreviations used in data labels: Met – Permethrin metabolite, 
Cyper – Cypermethrin, E2 - 17-estradiol, RC- Ripcord and NTC refers to No Treatment Control. 
Significance compared to NTC tested by paired-two-tailed Student’s t-test, p values  0.1 are indicated on 
the Figure. 
 
 
Generally, the exposure of mouse Sertoli cells to cypermethrin and the permethrin 
metabolite caused an increase in expression of both ER alpha and beta mRNA whereas 
exposure to estradiol resulted in a decrease in expression. Varying degrees of expression 
change resulted from the different concentrations of treatments however, most followed 
the same trend. The variation between what should be similar biological replicates is 
notable particularly for the replicates of Ripcord 36 M treatment (see Figure 15). Two of 
these replicates show an over 10-fold increase in ER mRNA expression however the 
third shows no relative change. The 36 M cypermethrin treatment resulted in a 
significant decrease in ER but in only one replicate and the other replicates failed to 
follow the same trend. A significant increase in the relative expression of both ER and 
ER for the permethrin metabolite at 0.69 nM is evident, however, both increases 
occurred in one replica only. Ripcord 0.36 nM treatment similarly resulted in a significant 
increase in both ER and ER for two of the replicates however the third replicate 
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exhibited a significant, though very minor, decrease. The results for the permethrin 
metabolite at 69 pM illustrate that the variability between the three PCR experiments, 
represented by the error bars, contributes to whether a change was statistically significant. 
For those replicas, the increased expression for ER in particular was very similar 
however only one change was significant. This reflects the fact that the larger the 
variability the less likely a t-test will be able to distinguish significant change from the 
variation in the control. Both concentrations of the estradiol treatments resulted in a 
decrease in expression of ER with the three individual cultures showing significant 
change. The change in ER expression was not as consistent at both concentrations 
though no changes were significant.  
 
3.6.2 Treatment Results 
 
The average fold-change data for individual cultures over three PCR experiments was 
averaged with other cultures of that specific treatment to show the overall treatment trend 
(see Figure 16). Hence the error bars represent the variation between separate biological 
replicas of each treatment. They are standard errors of the mean as the average over all 
PCR experiments for each culture was used in calculating the treatment average. 
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Figure 16 Average fold-change of ER alpha and ER beta by treatment (± SEM). Each treatment 
represents the average of the three replicate cultures, with the exception of the permethrin metabolite at 0.69 
nM which only had two cultures available. The cDNA made from each culture was run in three separate 
PCR experiments with triplicate culture samples in each. Abbreviations used in data labels: Met – 
Permethrin metabolite, Cyper – Cypermethrin, E2 - 17-estradiol, RC- Ripcord and NTC refers to No 
Treatment Control. Significance compared to NTC tested by paired-two-tailed Student’s t-test, p values  
0.1 are indicated on the Figure. 
 
 
Due to the averaging of quite disparate biological replicas the retention of significance for 
the average fold-change per treatment against any change in the control average is in itself 
notable. For ER expression two treatments resulted in a significant change (see Figure 
16). The permethrin metabolite at 69 pM caused an increase in ER mRNA expression 
whereas 17-estradiol at 10 nM caused a decrease relative to the non-treated control. ER 
expression only changed to a significant extent after treatment with Ripcord at 0.36 nM 
which caused an increase in fold-expression. Only the estradiol treatment at 10 nM 
resulted in receptor levels changing in different directions, all other treatments showed the 
same effect to varying degrees for both receptors. Some treatments that appear visually 
significant such as the fold-change of the ER expression after Ripcord treatment at 36 
M, are not statistically significant because of the large standard deviation. The large 
variability in this case was due to the fold-change not occurring in one of the biological 
replicas that were included in the averaging.  
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3.6.3 Ratio of Expression Fold-Change 
 
The ratio of ER expression fold-change to ER expression fold-change was calculated 
and plotted on Figure 17. This ratio indicates whether the relative expression level of 
either gene to the other has changed. A positive ratio change represents an increase in the 
difference between the net amounts of ER to ER whereas a negative ratio change 
indicates that the difference between the net amounts of ER to ER has decreased. 
Therefore if the ratio remains the same it can either indicate that there was no change in 
expression for either of the genes or that both changed but by the same degree. 
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Figure 17 Ratio of the fold change of ER alpha/ER beta expression (± SEM, n=3). Abbreviations used in 
data labels: Met – Permethrin metabolite, Cyper – Cypermethrin, E2 - 17-estradiol, RC- Ripcord and NTC 
refers to No Treatment Control. Significance compared to NTC tested by paired-two-tailed Student’s t-test, p 
values  0.1 are indicated on the Figure. 
 
 
After treatment with permethrin metabolite at 0.69 nM the mRNA expression levels of the 
estrogen receptors were altered resulting in a greater ratio between them (see Figure 17). 
As the ER receptor was consistently more highly expressed in all samples the increase in 
ratio indicates that either ER expression increased further or ER decreased thus making 
the overall balance further in the ER receptors favour. Comparison with Figure 16 
reveals that although the relative expression of ER and ER increased, the increase in 
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ER expression was significantly greater than the change in ER expression. While the 
other ratio changes were not statistically significant; the trend for both the estradiol 
concentrations was an increase in ratio, whereas, all other pyrethroid treatments, except, 
the permethrin metabolite at 0.69 nM, either showed a decrease or no change in ratio. 
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4 Discussion  
 
4.1 Estrogenicity of Pesticides as Determined by the Yeast Assay 
 
The yeast assay was used to test for potential estrogenic activities of pyrethroid chemicals 
that are licensed for use in New Zealand. Changes observed in this assay system may not 
represent the total response of cells because the model is limited to binding of chemicals 
to the estrogen receptor alpha (ER). Normal cells are known to have a second estrogen 
receptor, beta (ER) as well as an array of co-activators and repressors.  The yeast assay is 
a good system for preliminary screening for potential estrogenic activities of compounds.  
 
The current study found that, among the various pyrethroids tested in the yeast system, 
cypermethrin, bifenthrin and the permethrin metabolite were significantly estrogenic 
(Table 2). Of the remaining pyrethroids, permethrin, pyrethrin, Ripcord (cypermethrin) 
and cyfluthrin were found to be weakly estrogenic; however, these activities were not 
statistically significant. Taufluvalinate and deltamethrin were found to be non-estrogenic.  
 
4.1.1 Comparison of Results with Published Literature 
 
The majority of the literature related to the estrogenicity of the pyrethroids tested in this 
study, concentrates on the more commonly used pesticides such as cypermethrin and 
permethrin. Very few reports are available for cyfluthrin and deltamethrin and no reports 
on the estrogenicity of taufluvalinate and bifenthrin were found. In addition to these 
reports which are summarised in Table 5, the estrogenicity of pyrethrum of which 
pyrethrin is a component has been reported as well as the estrogenicity of the specific 
permethrin metabolite used in this study.  
 
Cypermethrin in this assay displayed both a strong visual colour change and statistical 
significance. However, there are contradictory results in the literature regarding its 
estrogenicity. Kojima et al. (2004) found that cypermethrin was estrogenic through the 
ER receptor but not ER. Chen et al. (2002) also reported cypermethrin to be estrogenic 
(Table 5). Both reports support the current findings that cypermethrin was estrogenic. 
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Conversely, other authors have reported cypermethrin to be non-estrogenic (Saito et al., 
2000, Nishihara et al., 2000, Kim et al., 2004 and also by Tyler et al., 2000).  
 
The current study found that permethrin had a weak but positive estrogenic response. This 
supports the findings of Tyler et al., 2000 who concluded permethrin to be a weak 
estrogen agonist. Conversely permethrin has been found to be non-estrogenic by Garey 
and Wolff 1998, Go et al., 1999, and Saito et al., 2000. 
 
In contrast to the parent compound, the permethrin metabolite that was used in this work, 
3-(4-hydroxyphenoxy)benzyl alcohol, was found to be significantly estrogenic displaying 
a very strong colour change. This confirms the findings of McCarthy et al., (2006) who 
also obtained a similar EC50 value for this specific metabolite (see Table 4). 
 
Bifenthrin was found to be one of the pyrethroids that induced a statistically significant 
colour response, however, the physiological significance of this is likely to be more 
heavily influenced by the fact that toxicity occurred within a fold higher concentration 
than that which was required to exhibit the estrogenic response. This suggests that any cell 
that is exposed to bifenthrin at what was found to be an estrogenic concentration maybe 
more likely to be affected by the beginnings of toxicity rather than any estrogenic 
influence. However, the physiological relevance of both the estrogenicity and the toxicity 
are increased because the bifenthrin used in this work was the active ingredient in a 
commercial product. Hence, compared to a purified laboratory chemical, there is a higher 
likelihood of exposure as the commercial product is sold over the counter for recreational 
garden use. Exposure to humans is less likely to cause toxicity due to our mass and 
physical barriers while the estrogenic potency of bifenthrin was the greatest amongst the 
pyrethroids at only 10,000-fold below that of estradiol. Other xeno-estrogens such as o,p’ 
- DDT and BPA are 30,000-fold and 17,000-fold less potent than estradiol in the yeast 
assay screen (Rajapakse et al. ,2001) highlighting the significance of bifenthrins potency. 
 
Cyfluthrin, in this work, exhibited a positive response (colour change) over a narrow 
concentration range, thought to be limited due to the chemicals toxicity. Kojima et al., 
(2004) have previously reported that cyfluthrin acted as an estrogen agonist through ER, 
which is consistent with the current finding. Deltamethrin showed no estrogenic response 
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in the yeast assay which is supported by Andrade et al., 2002; Kojima et al., 2004, where 
neither suggested any agonist activity.  
 
Taufluvalinate displayed no colour change although solubility issues may have 
contributed to this result. In this study, when ethanol was used as a solvent for the 
commercial product that contained taufluvalinate a white viscous body solidified in the 
solution, though most of this viscous body eventually dispersed. It is, nevertheless 
possible that the intended quantity of taufluvalinate was not accurately transferred to the 
assay wells. Thus, an alternate solvent may be more appropriate for taufluvalinate to 
confirm its lack of estrogenicity.  
 
Ripcord (cypermethrin) and pyrethrin showed a positive estrogenic activity as judged by 
the colour change, although these activities were not statistically significant. As there was 
no visually detectable colour change in the control, this suggests that these compounds are 
likely to be mildly estrogenic. While the chromogenic substrate used in the assay medium, 
CPRG (or its β-galactosidase degradation product chlorophenol red) has been shown to act 
as a weak estrogen (Vanderperren et al., 2001). This potential contamination was 
minimized by the short incubation time (48 hours) and monitored by the inclusion of a 
blank control in each experiment. 
 
The weak estrogenic activities observed in some of the compounds tested may be due to 
solubility, which would lower the bioavailability of these test chemicals to the yeast cell. 
There are suggestions that adsorption of chemicals into the plastic plates may occur or that 
the chemicals may be actively transported out of the cells by means of efflux pumps 
known to be active in the yeast cells (De Boever et al., 2001). The highly lipophilic nature 
of pyrethroids aids in their absorption through the cell membranes of mammalian cells 
however the presence of the yeast cell wall almost certainly alters their typical uptake and 
transportation (Rajapakse et al., 2001). Beresford et al. (2000), however, suggested that, 
where a submaximal response is observed in the yeast assay, it is most likely related to the 
binding affinity of the chemical to the estrogen receptor rather than any solubility or 
adsorption problems. Problems associated with solubility in the yeast assay and some 
specific chemicals such as DDT, and organochlorine have previously been encountered 
(Rajapaksi et al. 2001) as well as in this study as mentioned for taufluvalinate. 
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4.1.2 EC50 Comparison 
 
The EC50 value for 17-estradiol calculated from the data in this work was of the same 
order of magnitude as values reported in the literature (Table 3). The EC50 value of the 
permethrin metabolite determined in this study was consistent with that reported by 
McCarthy et al. (2006) who generously supplied the chemical for the present study (see 
Table 4). These comparisons confirm the accuracy of the assay in this work. 
 
Table 3 Comparison of the EC50 value of 17-Estradiol calculated in this work and values given in 
literature. 
EC50 17-Estradiol [M] Reference 
1.5 x 10
-10 
This work (2006) 
3.49 ± 0.16 x 10
-10
 McCarthy et al., 2006 
2.7 ± 0.93 x 10
-10
 Thomson, 2004 
1.3 x 10
-10
 Rajapakse et al., 2001 
1.44 x 10
-10
 – 10.78 x 10-10   De Boever et al., 2001 
2.1 ± 0.35 x 10
-10
 Tyler et al., 2000 
2.2 ± 0.22 x 10
-10
 Beresford et al., 2000 
2.0 x 10
-10
 Arnold et al., 1996 

95% confidence intervals. EC50 values are unique to the organism, all values in the table are from 
similar yeast assays. 
 
 
Table 4 Comparison of Permethrin Metabolite EC50 with literature value 
EC50 Permethrin Metabolite (M) 
(3-(4-hydroxy-phenoxy)benyl alcohol) 
Reference 
5.7 x10
-6
 This work 
6.75 ± 2.28 x 10
-6
 McCarthy et al., 2006 
 
Investigations have found that increasing the number of yeast cells or extending the 
incubation time has no effect on relative potency of chemicals compared to estradiol 
however it does effect the position of the dose response curves, shifting them to the left. 
Thus it has an effect on the EC50 values (Beresford et al., 2000). This effect could have 
contributed to the EC50 value of estradiol calculated in this work which was found to be 
slightly more potent compared to those reported in the literature, (see Table 3). The yeast 
batch from the Glaxo group used in this work had an increased growth rate as mentioned 
in the methods section. Thus even with the decreased inoculation volume, the final yeast 
concentration at the end of the incubation would have been expected to have been greater 
than that for slower batches used in other studies. 
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4.1.3 Influence of the Yeasts’ Metabolic Capabilities on the Pyrethroid 
Induced Responses  
 
The permethrin metabolite that was used in this work, 3-(4-hydroxyphenoxy)benzyl 
alcohol, as previously mentioned, was found to be significantly estrogenic confirming the 
findings of McCarthy et al., (2006). Previously another metabolite of permethrin, 3-
phenoxybenyl alcohol has also been found to be estrogenic by both McCarthy et al., 
(2006) and Tyler et al., (2000). As some of the metabolites of permethrin are proving to be 
more estrogenic than their parent compounds and this may to some extent explain the 
disparity of the parent compounds results. 
 
The weak response of permethrin observed in this work could reflect the yeasts ability to 
metabolise the compound to estrogenic metabolites. Hence the permethrin itself may not 
be estrogenic and the weak response could be accounted for by the accumulation of its 
metabolites. The submaximal response compared to its metabolite is consistent with the 
required metabolic conversion of permethrin which would delay the reporter genes 
response hence, limit the maximal absorbance over the short incubation period. 
Alternatively, permethrin may be weakly estrogenic in its own right and the degradation 
products could simply contribute to the colour development.  
 
Likewise, some metabolites of cypermethrin have also shown estrogenicity (McCarthy et 
al., 2006) however, the very strong colour change and good dose response curve seen for 
cypermethrin suggests that either the metabolic conversion was rapid or that the parent 
compound was estrogenic with potential additional estrogenic contribution from its 
metabolites. The metabolic capabilities of the different assays in Table 5 most likely 
contributed to the varied results for permethrin and cypermethrin. 
 
The disparity between the pure cypermethrin and the commercial cypermethrin that were 
both tested at the same concentrations may also be explained by the metabolic processes 
occurring. The lack of response from Ripcord cypermethrin could indicate that the yeast 
were unable to metabolise this compound. Unlike the pure compound the commercial 
product could contain a synergist chemical that are often used in combination with 
pyrethroids to enhance their performance as pesticides. Synergists such as piperonyl 
butoxide, which is licensed for use in New Zealand, act by inhibiting the activity of 
metabolic enzymes preventing the degradation of pyrethroids and hence, extending their 
 54 
persistence (NZFSA, 2004, Tomlin, 1994). As cypermethrin potentially requires metabolic 
conversion prior to exerting an estrogenic response a synergist may significantly block 
this process. 
 
4.1.4 Considerations Relevant to the Yeast Assay Model  
 
Phytoestrogens such as genistein and coumestrol have been shown to have higher affinity, 
approximately 20-fold and 7-fold respectively, for ER over ER through competitive 
binding assays (Kuiper and Gustafsson 1997, Kuiper et al., 1998, Mueller et al., 2003, 
Gruber et al., 2002). Thus there is potential for this yeast assay to underestimate the 
relative potencies of some chemicals as they might have a higher affinity for ER similar 
to the phytoestrogens. However, cypermethrin, permethrin, cyfluthrin and deltamethrin 
have all previously been shown to interact with ER but not ER (Kojima et al., 2004). 
The presence of only the alpha receptor in the yeast assay model is less likely to 
underestimate the pyrethroids estrogenicity compared to assaying phytoestrogens by the 
same method. 
 
The yeast assay identifies chemicals that bind to the estrogen alpha receptor however it 
does not directly indicate whether they act as agonists, antagonists or anti-estrogens. The 
yeast assay can identify some anti-estrogens by the co-treatment of estradiol with the test 
chemical (Routledge and Sumpter, 1997, Sohoni and Sumpter, 1998). A decrease in 
response significantly different from estradiols’ individual dose response thus shows 
potential anti-estrogenic activity of the test chemical. Amongst the disparate literature 
reports, anti-estrogenic activity has previously been found for cypermethrin, permethrin 
and deltamethrin (Table 5). Thus further experiments to investigate the pyrethroids effects 
on estradiols’ estrogenic activity would be of interest.  
 
The yeast assay can not identify all anti-estrogens, even when employing co-treatment 
with estradiol. For example the pure anti-estrogen, ICI 182,780, referred to as a type II 
anti-estrogen, is known to produce a purely agonistic response in the yeast screen with no 
inhibition of the estradiol-induced response. This lead Gaido et al., (1997) to suppose that 
the yeast may not contain the full complement of appropriate repressor proteins necessary 
for antagonism in this case. Considering the estrogen receptor was transfected into yeast 
cells which do not usually contain the estrogen receptor, the lack of necessary co-
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repressors and co-activators is likely. This lack of co-factors may also limit the response 
induced by some chemicals as they could require binding of the co-factors, to the ligand 
bound receptor, to further alter the receptors’ conformation and improve its binding to the 
estrogen response elements. Thus the yeast screen is not a comprehensive model however 
as long as its limitations are recognised it contributes valuable information to the complex 
process of risk assessment. 
 
 
 
 
 
  General Assay Type 
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Table 5 Summary of Literature Reporting Estrogenicity of some of the Pyrethroids used in this work 
 
 
  Reporter 
Gene  
E-Screen  
(MCF-7 
proliferation) 
Hershberger 
and 
Uterotrophic 
Other assays 
P
er
m
et
h
ri
n
 
     
Estrogenic Tyler et al., 
2000 
Go et al., 
1999 
Kim et al., 
2005 
 
 
 
 
Kojima et al., 
2004 
Chen et al., 
2002 
  
Non-estrogenic Nishihara et 
al., 2000 
Soto et al., 
1995 
Kunimatsu et 
al., 2002 
Garey and 
Wolff 1998 
 
 
 
Saito et al., 
2000 
   
Anti-estrogenic 
 
 Kim et al., 
2004 
  
C
y
p
er
m
e
th
ri
n
 
     
Estrogenic Kojima et al., 
2004 
Chen et al., 
2002 
  
     
Non-estrogenic Nishihara et 
al., 2000 
Kim et al., 
2004 
  
 
 
 
Saito et al., 
2000 
   
Anti-estrogenic 
 
Tyler et al., 
2000 
   
C
y
fl
u
th
ri
n
 
     
Estrogenic Kojima et al., 
2004 
   
     
Non-estrogenic 
 
Nishihara et 
al., 2000 
   
D
el
ta
m
e
th
ri
n
      
Anti- estrogenic 
 
Kojima et al., 
2004 
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4.2 Selection of Chemicals for Exposure of Mouse Sertoli Cells 
 
As a result of the yeast assay investigations, three chemicals plus estradiol and the ethanol 
control were chosen as treatments for the exposure of Sertoli cells. The chemicals that 
were selected were both the pure cypermethrin and the commercial compound containing 
cypermethrin - Ripcord - and the permethrin metabolite. There were various 
considerations as to why these chemicals were selected and at what concentrations were 
they to be used. Firstly not only did the permethrin metabolite and the cypermethrin 
induce near maximal estrogen receptor mediated β-galactosidase expression, thus a clear 
estrogenic response, but they were also the two pure chemicals and therefore lacked the 
complication of extensive contamination. On the other hand Ripcord cypermethrin, the 
garden solution, was diluted to give the same concentration of cypermethrin as the pure 
sample yet it did not induce a significant response. Thus the comparison between a 
laboratory chemical and a commercial gardening product, which is the more likely source 
of physiological exposure, was of interest. Although comparison between the permethrin 
metabolite and its parent compound was considered, the only permethrin available was 
from a garden preparation and thus comparison with the chemically synthesised 
metabolite would already include purity differences not related to the parent-metabolite 
relationship.  
 
The concentrations of the test chemicals were selected to examine both a high, non-
physiological dose effects and low dose effects designed to be within the reported 
physiological range of the chemicals. Physiological levels of estradiol are known to be 
higher in the male reproductive tract than in the general circulation. Estrogen levels in 
peripheral blood range from 0.002-0.18 g/L depending upon the species, whereas in one 
report, the estrogen concentration in the rete testis fluid of the rat was as high as 0.25 g/L 
(Reviewed in Hess 2003). The estradiol concentrations selected for this study were 300 
mg/L as a high dose and 3 g/L as a low dose. Although the low dose concentration is still 
ten-fold higher than the reported values, these levels fit well with other cell exposure 
studies where the concentrations varied from the milli-gram to the nano-gram range 
(Saceda et al., 1998, Robertson et al., 2002, Diel et al., 2002, Wozniak et al., 2005). The 
lower exposure concentration of 3 g/L estradiol is consistent with the Kd values for 
binding to both ER and ER by estradiol (Kuiper et al., 1997). 
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The consistent detection of pyrethroid metabolites in the urine from non-specifically 
exposed individuals indicates that physiological exposure to pyrethroids exists for the 
general population. These background levels of pyrethroid metabolites in urine have been 
investigated for various populations (Butte et al., 1998, Hardt et al., 1999, Heudorf and 
Angerer, 2001, Whyatt et al., 2003, Leng et al., 2003, Leng et al., 2006). For example, the 
extensive study by Heudorf and Angerer, 2001 who examined the metabolites in urine 
from over one thousand volunteers who were not occupationally exposed, nor had recent 
indoor exposure to pyrethroids, found metabolite levels corresponding with 95% values of 
0.3 to 1.5 g/L depending on the metabolite.  
 
It has been suggested that the pyrethroid metabolites detected in the general population are 
the result of dietary exposure thus, discrepancies between the detected levels of individual 
metabolites in different populations would be expected due to the variations in diet (Hardt 
et al., 1999, Heudorf and Angerer, 2001, Leng et al., 2003). This supports the findings of 
Heudorf and Angerers’ earlier work that the metabolite levels did not correlate with the 
pyrethroid levels as measured from the household dust. Dietary exposure was also 
corroborated by subsequent analysis of the same data set by Schettgen et al., 2002 who 
demonstrated that the ratio of metabolite isomers found in the urine was 2:1 in favor of the 
trans- isomer. This ratio is indicative of oral exposure whereas dermal exposure has been 
shown to result in an approximately equal ratio of isomers (Woolen et al., 1992). 
 
The exposure levels for pest control operators have also been measured by detection of 
metabolites in urine. The reported levels vary due to the specific chemical concentrations, 
different exposure periods and the times at which the samples were obtained. Leng et al., 
(1997) reported levels up to 277 g/L with a median level of 30 g/L however in their 
later studies (Leng et al., 2003, 2005) they found lower mean concentrations between 0.2-
13.4 g/L most likely due to safer application techniques. 
 
The concentrations chosen for the pyrethroid exposures in this study were 300 mg/L and 3 
g/L for all chemicals with an extra dilution of the permethrin metabolite to 0.3 g/L in 
this study. The 3 g/L concentration is clearly in the physiological range for the general 
population as the recovery of the metabolites (up to 1.5g/L) represents only a percentage 
of the actual pyrethroid exposure, (recovery is reported to be highly varied between 40 – 
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80% (Leng et al., 2006)). The high dose level 300 mg/L, is 100,000-fold higher than the 
physiological dose, and is well above the metabolite levels reported even for the pest 
control workers (highest reported as 277 g/L Leng et al., 1997). However the possible 
high dose effects are of interest as they reflect the fact that the potency of the pyrethroids 
to that of estradiol are up to a million fold lower. Thus the high dose concentration is 
closer to a level at which the pyrethroids may be capable of exerting an estrogenic 
response as predicted by the yeast assay results. Similarly, other researchers have 
examined chemicals at concentrations reflective of their relative potencies rather than their 
physiological levels. For example Diel et al., (2002) when examining the effects of 
raloxifene, coumestrol, DDT, and BPA on MCF-7 cells and likewise Kakko et al., (2004) 
when examining the affects of permethrin, cypermethrin and pyrethrin on SH-SY5Y 
neuroblastoma cells. 
 
The concentrations chosen for the chemical exposures to the Sertoli cells were not all 
evaluated using the yeast assay as summarised in Table 6. Thus none of the pyrethroids 
were tested at concentrations as low as those used in the Sertoli cell exposures. 
Extrapolation from the responses at the higher concentrations suggests that the 
concentrations would be too low to exhibit any detectable estrogenic affect via the yeast 
assay. Therefore, if estrogenicity in the yeast assay is predictive of cellular responses to 
estrogens; the exposure of mouse Sertoli cells to the high doses were expected to affect the 
estrogen receptors expression where as the low doses were expected to be effectively 
similar to the non treated cells. Despite the yeast assay no-effect prediction, the inclusion 
of the low dose exposures are key investigations because although the low concentrations 
of pyrethroids would be unlikely to show any response in the yeast assay model, the 
mouse Sertoli cells offer a higher degree of biological complexity that may affect the 
potency of the chemicals. 
 
Differences between the yeast model and the mouse Sertoli cells have the potential to 
affect the potencies of the pyrethroids due to differences in the expression level of ER as 
well as the presence of the -subtype, the availability of specific co-factors and different 
metabolic capabilities. Support for observing chemicals at concentrations below the 
predicted no dose effect was reviewed by Welshons et al., (2003) who highlighted the 
error in extrapolating from the high toxicological doses commonly tested in risk 
assessment. In particular they presented evidence on inverted-U dose-response 
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relationships observed for some chemicals where the effects induced are different at high 
and low concentrations. For example the MCF-7 cell line exhibits estrogen-dependent 
stimulation of cell proliferation by natural and xenobiotic estrogens however the same 
chemicals that stimulate the growth at low concentrations can slow MCF-7 growth at 
higher concentrations (Welshons et al., 2003 and references there in). 
 
 
Table 6 Summary of the chemicals and concentrations used in the Sertoli cell exposures relative to 
their yeast assay dose responses 
Chemical Concentration used in 
cell exposures 
Response in yeast assay at the 
corresponding concentrations

 
Estradiol 300 mg/L 100 % 
 3 g/L 40 % 
Cypermethrin 300 mg/L 1 % 
              3 g/L             Not Tested 
Ripcord (cypermethrin) 300 mg/L No Response 
 3 g/L Not Tested 
Permethrin Metabolite            300 mg/L          

 50 % 
 3 g/L Not Tested 
 0.3 g/L Not Tested 
 
The percentages given indicate the approximate amount of receptor activation at that concentration 
determined by the increase in absorbance in the yeast assay. 

 Gene expression of the cells from of these treatments could not be quantified due to low yield.  
 
4.3 Pyrethroids effect on mouse Sertoli cells 
 
4.3.1 Variations between observed cell densities and extracted RNA yields  
 
Comparison between the approximate cell density of the cultures prior to harvest and the 
yield of RNA reveals some inconsistencies. The cultures exposed to the permethrin 
metabolite treatment that exhibited either toxicity or growth inhibition showed the 
expected reduced RNA yield that was predicted due to the lower number of cells. 
Likewise, the Ripcord cypermethrin treatment had a slight effect on the cell growth at both 
concentrations which was also reflected in the RNA yields. However the pure 
cypermethrin treatments resulted in surprisingly low RNA yields despite the high cell 
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numbers observed for both concentrations of the treatment. For the pure cypermethrin 
treated cultures, the difference in RNA yield compared to the control cells, of 
approximately equal confluence, was greater than could be attributed to a decrease 
transcriptional activity, even if the cells had been in a stationary phase. Thus the extremely 
low yield suggested a problem with the extraction of RNA from these samples.  
 
The extraction of the RNA samples was performed in four batches. One of these batches 
included all of the pure cypermethrin treatments but only two of the samples for the 
estradiol treatment at 0.3nM. Thus it is likely that a handling problem specific to when this 
batch was extracted, affected the yields of RNA for these samples. This is supported by 
the much higher RNA concentration of the third estradiol sample at 0.3nM that was 
extracted on a separate occasion.  
 
Although extraction problems are suspected for the pure cypermethrin treatments and two 
of the estradiol samples, the low yield from other samples such as from the permethrin 
metabolite treatment at 69 M, was thought to be purely related to the very few cells 
present at harvesting. Despite taking steps to concentrate the low RNA yield from these 
samples, neither the permethrin metabolite at 69 M treatment samples nor the pure 
cypermethrin at 0.36 nM treatment samples were able to be amplified. 
 
The RNA quantification was shown to be relatively accurate based on the low variation 
within the raw Ct values of the -actin product gained from the subsequent RT-PCR 
amplification of the samples. Although indirect, the correct dilution of cDNA - as shown 
by the similar -actin raw Ct values - supports the initial quantification data. 
 
Interestingly, the slight increase in growth, relative to the control cells, induced by the 
high concentrations estradiol as seen by the cell photographs was supported by increased 
RNA yield from two of the estradiol cultures compared to the control. Increase in growth 
was also observed for Ripcord cypermethrin at high concentrations however, the RNA 
yields suggest this effect was only substantial in one of the cultures thus a more variable 
response. 
 
 
 
 62 
 
4.3.2 Potential Mechanisms for the Pyrethroid treatments effects on mouse 
Sertoli Cell growth 
 
Despite the inconsistencies that have been accounted for, the growth of mouse Sertoli cells 
was clearly affected by their exposure to some of the pyrethroid treatments. The greatest 
effect, as seen by the cell photographs, resulted from the permethrin metabolite treatment 
followed by Ripcord, whereas no obvious cytotoxicity was observed as a result of the pure 
cypermethrin or estradiol treatments relative to the control cultures. The toxicity could 
have resulted from the pyrethroids pesticide properties rather than any estrogenic affects 
however mediation of apoptosis via the estrogen receptor has previously been shown for 
both xeno-estrogens and endogenous estrogens. 
 
4.3.2.1 Possible contributions of insecticidal properties of pyrethroids to toxicity 
 
At the cellular level the important target sites of pyrethroids in mammals are the cell 
membrane and specifically the sodium channels (reviewed in Raymond-Delpech et al., 
2005). Cells differ in their sensitivity to pyrethoids due to the multiple sodium channel 
isoforms that vary in their biophysical and pharmacological properties within and between 
species (Kakko et al., 2004). Significant toxicity was not observed in the yeast assay from 
either of the cypermethrin compounds however, the presence of the yeast cell wall most 
likely afforded the yeast a higher level of protection than the mammalian cell membrane 
which readily absorbs the highly lipophilic pyrethroids.  
 
The toxicity of Ripcord cypermethrin to mammalian cells has previously been investigated 
by Kakko et al., 2004 using a neural cell line SH-SY5Y. Concentrations of Ripcord 
ranging from 10 M up to 100 M showed significant morphological changes eventually 
resulting in the rounding-up of the neural cells indicating extensive toxicity. In 
comparison, the current study observed a decrease in cell density compared to the control 
cells, for cultures treated with 0.36 nM of Ripcord. This decrease in cell density may 
indicate toxicity however the gross morphology of the cells did not change. At the higher 
exposure concentration, 36 M, no toxicity or decrease in density was observed in the 
Sertoli cells whereas toxicity increased with dose in the neural cell line. Hence it appears 
that the Sertoli cells were less sensitive to Ripcord cypermethrin than the neural cell line.  
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In addition, pyrethroid metabolism involves the formation of reactive oxygen species 
which increases oxidative stress and can trigger or contribute to apoptosis (Kale et al., 
1999). Thus apart from the actions at the cell membrane, cypermethrin could further affect 
the cells due to its metabolism. 
 
4.3.2.2 Involvement of Estrogenic mechanisms in toxicity of pyrethroids 
 
The permethrin metabolite showed the greatest toxicity compared to both the Ripcord and 
pure cypermethrin. The permethrin metabolite lacks key structural features required for 
pyrethroid like function yet it has been shown to possess the ability to bind and activate 
the human estrogen receptor in the yeast assay. Therefore, in regards to this chemical, the 
toxicity observed could be linked with the binding to the estrogen receptors rather than 
classic pyrethroid toxicity. Direct interaction with the estrogen receptors has previously 
been implicated in the apoptotic signally pathways in the testes and thus may explain the 
notable cell death seen in this study (Pentikainen et al., 2000). 
 
4.4 ER and ER expression in Sertoli Cells 
 
Generally speaking the exposure of mouse Sertoli cells to cypermethrin and the 
permethrin metabolite caused an increase in expression of both ER and  whereas 
exposure to estradiol resulted in a decrease in expression. The different concentrations 
produced varying degrees of changes however overall it appears that the effect of the 
xenoestrogens was not the same as the effect of estradiol. This may reflect different 
transactivation and subsequent autoregulation properties of the ER when bound to these 
different ligands. The lack of relationship between the expression changes and toxicity 
observed also suggests that the expression changes were independent of the toxicity and 
vice versa.  
 
The real-time RT-PCR indicated that ER mRNA is predominately expressed over the 
ER mRNA in TM4 mouse Sertoli cells under all treatments. This finding contradicts the 
publish literature where only ER has been found to be localised in adult mouse Sertoli 
cells (Makinen et al., 2001). The presence of both receptors may be an artefact of the TM4 
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cells being a permanent cell line which, in its establishment, could have altered the 
estrogen responsiveness. Suppression of both ER (Lau et al., 2000) and ER (Skliris 
2003, Zhao 2003) expression dependent on the cell type has been shown to occur via gene 
silencing by methylation of the promoter sequences (Sasaki et al., 2002). This is a 
reversible process and exposing cells to de-methylating agents restores expression of both 
mRNA and protein. 
 
The different expression of the estrogen receptors compared to previous reports is an 
important factor in determining the physiological significance of these results. The 
presence of both receptors increases the possible signally pathways that the pyrethroids or 
estradiol could be involved in. Estrogen receptors when co-localised within the same cell 
have been shown to form heterodimers, and moderating effects of ER on ER become 
possible (Matthews and Gustafsson, 2003). 
 
The implications of changes in estrogen receptor expression for male infertility are at this 
stage speculative yet comparison with the more thoroughly investigated changes in ER 
expression in cancer may provide some insights. A comprehensive review of changes in 
ER expression in tissues such as breast, ovaries, prostate and colon, that are proposed to 
be subject to estrogen mediated tumour progression demonstrated that the overall trend 
was an increase in the ratio of ER to ER expression(Bardin et al., 2004). This was 
almost always a result of decreases in ER  and or complete loss of expression. Increases 
in ER occurred in both the ovary and breast tissue but not change occurred in the 
prostate or colon. This most likely reflects that ER is not highly expressed in normal 
cells in these tissues compared to breast and ovary expression (Bardin et al., 2004). 
 
Although spermatogenesis is a very different process to cancer growth both involve cell 
proliferation. Spermatogenesis is a tightly controlled process of cell growth and 
differentiation much like normal tissues. Cancer on the other hand is a situation of 
uncontrolled cell growth. It could then be suggested that infertility is a state of “over-
controlled” cell growth.  
 
It has been found that infertile men have higher serum concentrations of estrogen. 
Whether the increase in estradiol observed is a result of the infertility originating from 
other factors, or a cause of the infertility is unknown. If the increased estrogen 
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concentration is found to be a large contributor to the infertility in these men rather than a 
subsequent side effect, the mechanism of estrogens action could possibly be through 
“over-control” of spermatogenesis. This could occur due to increased ERβ expression as a 
result of the increased estrogen concentrations by estrogen activating the additional 
transcription of the receptor.   
 
In the current study the estrogenic exposure of mouse Sertoli cells resulted in a significant 
ratio change of ER mRNA expression for the permethrin metabolite. The increase in ratio 
was a result of increased ER alpha and beta expression however, the relative increase in 
ER was greater. According to the cancer studies ER is the growth promoter whereas 
ER is the inhibitor or controller. Thus if comparison with the expression in other cell 
types and cancer progression is in any way indicative of testicular growth control then the 
ratio change would suggest a pro-growth environment. Thus, in this context the ratio 
change would be beneficial to spermatogenesis however arriving at that conclusion 
encompassed a large cohort of assumptions and speculations. 
 
Although the ratio change for the estradiol treatments were not significant the relative 
expression level of ER decreased. In relation to male infertility, estradiol has been shown 
to act as a survival factor decreasing programmed cell death. This process could be 
enabled by decreasing the growth control of ER through suppressing mRNA expression. 
 
Conclusions as to implications for male infertility are severely limited by the complexity 
of the estrogen signalling pathways and the vast amount of information still to be 
obtained. Despite this, the results of this study suggest that xenoestrogens do not effect 
estrogen receptor expression in the same way as the endogenous estrogen 17-estradiol in 
mouse Sertoli cells.  
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6 Appendices   
6.1 Yeast Assay Raw Data  
 
Chemical Concentration Raw Data Replicates 
        
Estradiol 4.92E-12 1.300 1.418 1.292 1.175 1.187 1.390 
 9.84E-12 1.551 1.582 1.573 1.170 1.205 1.685 
 1.97E-11 1.568 1.711 1.683 1.222 1.293 1.929 
 3.94E-11 1.719 1.993 2.099 1.273 1.418 1.859 
 7.87E-11 2.205 2.087 2.250 1.452 1.653 2.009 
 1.57E-10 2.247 2.328 2.466 1.674 1.906 2.311 
 3.15E-10 2.539 2.603 2.465 1.444 2.225 2.530 
 6.3E-10 2.520 2.706 2.556 2.096 2.330 2.424 
 1.26E-09 2.561 2.642 2.524 2.421 2.465 2.640 
 2.52E-09 2.543 2.673 2.570 2.402 2.480 2.591 
 5.04E-09 2.465 2.682 2.502 2.493 2.506 2.610 
 1.01E-08 3.096 2.593 2.395 2.507 2.479 2.137 
        
 4.92E-12 1.157 1.171 1.093 1.415 1.171 1.391 
 9.84E-12 1.204 1.220 1.083 1.076 1.109 1.488 
 1.97E-11 1.226 1.319 1.096 1.065 1.144 1.632 
 3.94E-11 1.354 1.438 1.131 1.112 1.154 1.855 
 7.87E-11 1.593 1.618 1.201 1.160 1.304 2.034 
 1.57E-10 1.756 1.769 1.311 1.257 1.461 2.276 
 3.15E-10 1.996 2.074 1.448 1.385 1.654 2.390 
 6.3E-10 2.078 2.139 1.618 1.526 1.907 1.350 
 1.26E-09 2.229 2.169 1.814 1.623 2.015 2.583 
 2.52E-09 2.245 2.214 2.141 2.023 2.104 2.606 
 5.04E-09 2.362 2.193 2.077 2.452 2.231 2.643 
 1.01E-08 2.463 2.243 1.830 2.563 1.853 2.722 
        
 4.92E-12 1.362 0.907 1.292 1.441 1.392 1.366 
 9.84E-12 1.465 1.114 1.207 1.275 1.489 1.468 
 1.97E-11 1.530 1.180 1.216 1.368 1.634 1.533 
 3.94E-11 1.671 1.294 1.320 1.413 1.861 1.678 
 7.87E-11 1.864 1.439 1.437 1.747 2.042 1.870 
 1.57E-10 2.060 1.677 1.672 2.045 2.279 2.069 
 3.15E-10 2.053 1.922 1.897 2.316 2.392 2.086 
 6.3E-10 2.487 2.079 2.090 2.478 1.352 2.504 
 1.26E-09 2.574 2.155 2.024 2.524 2.576 2.577 
 2.52E-09 2.620 2.363 2.361 2.447 2.602 2.639 
 5.04E-09 2.646 2.454 2.416 2.523 2.639 2.650 
 1.01E-08 2.725 2.411 2.498 2.682 2.692 2.749 
        
Taufluvalinate 1.4E-08 1.026 1.303 1.136 1.375 1.056 
 2.8E-08 1.128 1.330 1.138 1.447 1.044 
 5.59E-08 1.091 1.340 1.143 1.519 1.071 
 1.12E-07 1.079 1.343 1.145 1.472 1.070 
 2.24E-07 1.094 1.345 1.156 1.430 1.066 
 4.47E-07 1.080 1.335 1.155 1.393 1.075 
 8.95E-07 1.092 1.347 1.146 1.354 1.090 
 1.79E-06 1.062 1.340 1.167 1.349 1.094 
 3.58E-06 0.900 1.336 1.152 1.387 1.084 
 7.16E-06 0.875 1.331 1.157 1.295 1.087 
 1.43E-05 0.705 1.358 1.174 1.388 1.104 
 2.86E-05 1.076 1.453 1.020 1.320 1.093 
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Cyfluthrin 1.12E-08 1.098 1.198 1.024   
 2.25E-08 1.121 1.341 1.014   
 4.5E-08 1.129 1.310 1.032   
 8.99E-08 1.282 1.224 1.034   
 1.8E-07 1.319 1.248 1.059   
 3.6E-07 1.276 1.207 1.057   
 7.2E-07 1.214 1.041 1.063   
 1.44E-06 1.211 1.016 1.103   
 2.88E-06 1.323 1.008 1.097   
 5.76E-06 1.174 1.014 1.043   
 1.15E-05 1.096 1.030 1.025   
 2.3E-05 1.091 1.026 1.026   
       
Permethrin 1.87E-08 1.253 1.023 1.246   
 3.74E-08 1.257 1.015 1.211   
 7.49E-08 1.263 1.018 1.230   
 1.5E-07 1.259 1.012 1.228   
 2.99E-07 1.259 1.020 1.238   
 5.99E-07 1.254 1.016 1.236   
 1.2E-06 1.270 1.019 1.242   
 2.4E-06 1.281 1.026 1.236   
 4.79E-06 1.380 1.020 1.252   
 9.58E-06 1.364 1.019 1.268   
 1.92E-05 1.360 1.033 1.336   
 3.83E-05 1.443 1.052 1.163   
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Pure 
Cypermethrin 1.76E-08 1.150 1.142 1.151 0.912 1.060 
 3.52E-08 1.135 1.147 1.144 0.905 1.075 
 7.04E-08 1.151 1.162 1.132 0.907 1.078 
 1.41E-07 1.144 1.175 1.113 0.904 1.073 
 2.81E-07 1.165 1.188 1.113 0.911 1.077 
 5.63E-07 1.174 1.177 1.103 0.927 1.082 
 1.13E-06 1.197 1.210 1.128 0.910 1.085 
 2.25E-06 1.202 1.219 1.153 0.966 1.109 
 4.5E-06 1.263 1.263 1.160 0.993 1.134 
 9.01E-06 1.335 1.352 1.144 1.049 1.157 
 2.25E-05 1.083 1.465 1.228 1.315 1.471 
 4.5E-05 1.082 1.556 1.261 1.395 1.555 
 9.01E-05 1.130 1.689 1.340 1.552 1.698 
 0.00018 1.186 1.900 1.456 1.602 1.895 
 0.00036 1.339 2.141 1.652 1.801 2.058 
       
Ripcord 
Cypermethrin 1.76E-08 1.106 1.361 1.364 1.192  
 3.52E-08 1.101 1.383 1.391 1.276  
 7.04E-08 1.118 1.367 1.413 1.260  
 1.41E-07 1.104 1.389 1.404 1.238  
 2.81E-07 1.109 1.375 1.372 1.243  
 5.63E-07 1.093 1.371 1.383 1.246  
 1.13E-06 1.111 1.380 1.390 1.235  
 2.25E-06 1.115 1.391 1.412 1.272  
 4.5E-06 1.121 1.387 1.434 1.212  
 9.01E-06 1.128 1.413 1.412 1.197  
 2.25E-05 1.084 1.388 1.412 1.272  
 4.5E-05 1.080 1.459 1.434 1.212  
 9.01E-05 1.073 1.445 1.412 1.197  
 0.00018 1.094 1.475 1.454 1.218  
 0.00036 1.088 1.457 1.453 1.296  
       
Permethrin 
Metabolite 4.52E-08 1.116 1.327 1.247 1.211 1.177 
 9.03E-08 1.129 1.349 1.238 1.233 1.173 
 1.81E-07 1.147 1.379 1.311 1.257 1.224 
 3.61E-07 1.160 1.384 1.357 1.195 1.314 
 7.23E-07 1.186 1.404 1.397 1.268 1.384 
 1.81E-06 1.239 1.362 1.555 1.105 1.396 
 3.61E-06 1.317 1.784 1.851 1.127 1.503 
 7.23E-06 1.584 2.088 2.066 1.191 1.707 
 1.45E-05 1.720 2.425 2.190 1.256 1.919 
 2.89E-05 1.997 2.462 2.235 1.356 2.120 
 5.78E-05 2.121 2.526 2.304 1.434 2.284 
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Pyrethrin 3.17E-08 1.174 1.300 1.060 1.315 
 6.33E-08 1.172 1.349 1.075 1.311 
 1.27E-07 1.185 1.319 1.087 1.299 
 2.53E-07 1.162 1.295 1.088 1.283 
 5.06E-07 1.190 1.298 1.103 1.254 
 1.01E-06 1.144 1.266 1.075 1.222 
 2.03E-06 1.181 1.295 1.094 1.241 
 4.05E-06 1.155 1.292 1.061 1.254 
 8.1E-06 1.147 1.349 1.111 1.265 
 1.62E-05 1.154 1.399 1.152 1.368 
 3.24E-05 1.187 1.527 1.208 1.409 
 6.48E-05 1.243 1.583 1.171 1.248 
      
Bifenthrin 1.73E-09 1.179 1.253 1.267 1.452 
 3.46E-09 1.176 1.210 1.252 1.231 
 6.93E-09 1.187 1.138 1.261 1.216 
 1.39E-08 1.193 1.271 1.251 1.229 
 2.77E-08 1.212 1.268 1.265 1.233 
 5.54E-08 1.215 1.233 1.270 1.233 
 1.11E-07 1.233 1.272 1.269 1.259 
 2.22E-07 1.270 1.185 1.366 1.298 
 4.43E-07 1.294 1.322 1.475 1.262 
 8.87E-07 1.451 1.503 1.664 1.296 
 1.77E-06 1.238 1.391 1.743 1.636 
 3.55E-06 1.154 1.263 1.295 1.225 
      
Deltamethrin 1.45E-08 1.117 1.104 1.044 1.131 
 2.9E-08 1.096 1.132 1.043 1.132 
 5.8E-08 1.103 1.155 1.062 1.132 
 1.16E-07 1.128 1.158 1.068 1.135 
 2.32E-07 1.107 1.154 1.075 1.143 
 4.64E-07 1.105 1.153 1.078 1.147 
 9.28E-07 1.111 1.160 1.081 1.140 
 1.86E-06 1.104 1.156 1.088 1.169 
 3.71E-06 1.120 1.160 1.085 1.164 
 7.42E-06 1.108 1.160 1.089 1.158 
 1.48E-05 1.123 1.174 1.093 1.022 
 2.97E-05 1.190 1.184 1.060 0.947 
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6.2 Raw Data for SRB Growth curve assay 
 
Initial Cell Number 475000 237500 118750 59375 29688 14844 
Day O Rep 1 2.999 2.576 1.407 0.866 0.387 0.263 
 Rep 2 3.027 2.846 1.660 1.009 0.465 0.292 
 Rep 3 3.031 2.822 2.099 1.205 0.668 0.369 
Day 1 Rep 1 2.979 2.914 2.59 1.618 0.881 0.487 
 Rep 2 2.819 2.911 2.475 1.455 0.666 0.385 
 Rep 3 3.05 2.81 2.511 1.376 0.783 0.435 
Day 2 Rep 1 2.761 1.944 1.229 0.509 0.294 0.171 
 Rep 2 2.822 2.183 1.279 0.769 0.425 0.239 
 Rep 3 2.827 2.054 0.0975 0.619 0.334 0.193 
Day 3 Rep 1 2.927 2.938 2.763 2.37 1.595 0.471 
 Rep 2 2.94 2.935 2.763 2.447 1.585 0.849 
 Rep 3 2.22 2.668 1.949 1.177 0.669 0.342 
Day 4 Rep 1 3.141 3.127 3.065 3.108 3.075 2.92 
 Rep 2 3.207 3.174 3.22 3.108 3.084 3.041 
 Rep 3 3.117 3.02 3.091 3.099 3.075 2.883 
Day 5 Rep 1 3.135 3.225 3.108 3.224 3.135 3.109 
 Rep 2 2.971 3.076 3.051 3.262 3.071 3.086 
 Rep 3 3.066 3.085 3.142 3.111 3.193 3.143 
 
Initial Cell Number 7422 3711 1855 928 464 232 
Day O Rep 1 0.119 0.086 0.084 0.062 0.065 0.263 
 Rep 2 0.118 0.087 0.076 0.063 0.068 0.292 
 Rep 3 0.146 0.111 0.092 0.074 0.066 0.369 
Day 1 Rep 1 0.161 0.127 0.084 0.078 0.068 0.487 
 Rep 2 0.166 0.109 0.085 0.075 0.073 0.385 
 Rep 3 0.134 0.09 0.091 0.076 0.073 0.435 
Day 2 Rep 1 0.08 0.061 0.064 0.063 0.057 0.171 
 Rep 2 0.128 0.088 0.08 0.064 0.074 0.239 
 Rep 3 0.094 0.078 0.068 0.063 0.063 0.193 
Day 3 Rep 1 0.146 0.1 0.096 0.087 0.069 0.471 
 Rep 2 0.274 0.161 0.12 0.129 0.103 0.849 
 Rep 3 0.137 0.088 0.079 0.072 0.076 0.342 
Day 4 Rep 1 0.98 0.43 0.226 0.147 0.11 2.92 
 Rep 2 0.949 0.377 0.305 0.174 0.155 3.041 
 Rep 3 0.711 0.39 0.16 0.135 0.096 2.883 
Day 5 Rep 1 1.995 0.617 0.301 0.161 0.128 3.109 
 Rep 2 1.767 0.885 0.349 0.144 0.132 3.086 
 Rep 3 2.213 0.836 0.366 0.129 0.153 3.143 
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6.3 PCR Raw Ct Values   
 
6.3.1 PCR Experiment 1 
 
 
No. Sample  -Actin ER ER No. Sample  -Actin ER ER 
1 Met 69 pM 21.05 28.93 35.79 21 E2 10 nM 19.46 27.6 35.77 
1 Met 69 pM 22.01 29.3 36.27 21 E2 10 nM 19.9 27.58 38.52 
1 Met 69 pM 21.47 28.63 35.6 21 E2 10 nM 20.72 28.01 38.49 
2 Met 69 pM 21.27 28.48 35.57 22 RC 0.36 nM 20.94 27.51 34.58 
2 Met 69 pM 21.69 28.19 35.88 22 RC 0.36 nM 20.71 26.75 34.69 
2 Met 69 pM 21.72 28.31 36.58 22 RC 0.36 nM 20.76 27.88 34.92 
3 Met 69 pM 20.7 26.65 35.25 23 RC 0.36 nM 21.3 27.84 36.05 
3 Met 69 pM 20.89 26.94 35.69 23 RC 0.36 nM 20.51 27.91 35.74 
3 Met 69 pM 21.14 27.31 36.17 23 RC 0.36 nM 20.3 27.46 34.13 
4 Met 0.69 nM 22.55 28.24 38.82 24 RC 0.36 nM 19.43 26.78 35.36 
4 Met 0.69 nM 22.18 27.93 39.57 24 RC 0.36 nM 19.29 26.37 34.72 
4 Met 0.69 nM 22.47 28.57 39.21 24 RC 0.36 nM 19.24 27.11 34.7 
6 Met 0.69 nM 23.31 27.38 37.05 25 RC 36 uM 21.78 30.56 30.34 
6 Met 0.69 nM 23.56 27.78 37.69 25 RC 36 uM 22.35 30.28 30.6 
6 Met 0.69 nM 23.82 27.96 38.4 25 RC 36 uM 22.36 31.46 30.63 
13 Cyper 36uM 23.66 30.34 38.4 26 RC 36 uM 20.28 27.3 34.83 
13 Cyper 36uM 23.73 30.54 38.87 26 RC 36 uM 19.98 26.31 34.32 
13 Cyper 36uM 23.62 29.78 38.55 26 RC 36 uM 20.66 27.56 34.42 
14 Cyper 36uM 21 27.42 36.38 27 RC 36 uM 21.9 29.54 34 
14 Cyper 36uM 19.91 27.17 36.14 27 RC 36 uM 21.77 29.69 34.13 
14 Cyper 36uM 20.57 27.54 36.44 27 RC 36 uM 21.9 28.91 34.94 
15 Cyper 36uM 21.28 30.84 38.68 28 NTC 21.3 28.94 36.65 
15 Cyper 36uM 21.97 32.37 40.01 28 NTC 21.68 28.53 37.18 
15 Cyper 36uM 21.69 31.34 39.06 28 NTC 22.24 29.95 38.25 
16 E2 0.3 nM 21.65 28.92 38.71 29 NTC 20.63 28.66 36.12 
16 E2 0.3 nM 20.76 28.12 37.98 29 NTC 21 29.06 36.54 
16 E2 0.3 nM 21.07 28.55 39.03 30 NTC 20.93 29.09 35.67 
17 E2 0.3 nM 21.67 31.78 39.62 30 NTC 20.61 29.32 36.21 
17 E2 0.3 nM 22.36 34.97 39.61 21 NTC 20.83 28.88 35.94 
17 E2 0.3 nM 22.71  39.95 21 NTC 21.22 29.82 36.81 
18 E2 0.3 nM 21.89 28.05 38.74  
18 E2 0.3 nM 20.93 28.38 39.72  
18 E2 0.3 nM 21.08 28.28 38.9  
19 E2 10 nM 20.24 28.41 36.64  
19 E2 10 nM 20.82 28.14 37.2  
19 E2 10 nM 20.91 27.8 37.24  
20 E2 10 nM 18.8 26.41 35.94  
20 E2 10 nM 19.28 25.46 36.65  
20 E2 10 nM 19.47 26.64 37.14  
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6.3.2 PCR Experiment 2  
 
 
No. Sample  -Actin ER ER No. Sample  -Actin ER ER 
1 Met 69 pM 22.44 28.24 35.16 21 E2 10 nM 21.95 27.75 38.24 
1 Met 69 pM 22.3 27.78 35.32 21 E2 10 nM 21.5 28.06 37.13 
1 Met 69 pM 22.08 28.53 35.67 21 E2 10 nM 21.82 28.37 36.42 
2 Met 69 pM 21.82 27.24 34.75 22 RC 0.36 nM 21.5 26.84 34.87 
2 Met 69 pM 21.76 27.79 35.21 22 RC 0.36 nM 21.85 26.43 35.14 
2 Met 69 pM 21.78 26.55 34.43 22 RC 0.36 nM 21.84 25.8 35.42 
3 Met 69 pM 21.86 26.73 34.74 23 RC 0.36 nM 22.64 27.49 36.54 
3 Met 69 pM 22.34 26.96 34.93 23 RC 0.36 nM 21.7 27.68 37.04 
3 Met 69 pM 21.92 26.74 34.71 23 RC 0.36 nM 22.15 27.22 36.96 
4 Met 0.69 nM 22.71 27.68 36.41 24 RC 0.36 nM 20.39 26.17 35.32 
4 Met 0.69 nM 22.93 26.84 36.58 24 RC 0.36 nM 20.14 25.91 34.85 
4 Met 0.69 nM 23.16 27.69 37.02 24 RC 0.36 nM 19.92 25.54 34.79 
6 Met 0.69 nM 23.7 27.62 37.11 25 RC 36 uM 22.42 28.12 31.19 
6 Met 0.69 nM 23.98 27.82 37.65 25 RC 36 uM 22.96 28.18 30.93 
6 Met 0.69 nM 25.73 28.27 38.98 25 RC 36 uM 23.88 29.14 30.74 
13 Cyper 36uM 23.5 28.98 37.09 26 RC 36 uM 20.68 25.32 34.9 
13 Cyper 36uM 24.57 30.38 37.33 26 RC 36 uM 19.97 25.44 34.09 
13 Cyper 36uM 22.54 29.05 36.41 26 RC 36 uM 19.91 25.14 33.27 
14 Cyper 36uM 20.98 27.34 35.75 27 RC 36 uM 23.48 27.85 32.89 
14 Cyper 36uM 20.77 26.99 34.56 27 RC 36 uM 23.68 28.1 33.4 
14 Cyper 36uM 20.91 26.9 34.71 27 RC 36 uM 24.2 29.06 34.2 
15 Cyper 36uM 22.02 31.95 36.64 28 NTC 21.57 26.24 35.95 
15 Cyper 36uM 21.63 32.9 35.82 28 NTC 20.98 25.71 35.76 
15 Cyper 36uM 22.58 34.29 37.64 28 NTC 20.91 26.28 35.09 
16 E2 0.3 nM 22.25 28.09 36.5 29 NTC 20.52 26.63 34.72 
16 E2 0.3 nM 20.59 27.64 35.61 29 NTC 20.87 26.84 35.45 
16 E2 0.3 nM 20.75 27.9 36.21 30 NTC 20.88 26.92 35.87 
17 E2 0.3 nM 22.9  36.13 30 NTC 20.81 27.1 36.26 
17 E2 0.3 nM 22.14 43.59 36.4 21 NTC 20.64 26.95 36.14 
17 E2 0.3 nM 23.7  36.74 21 NTC 20.64 27.11 34.94 
18 E2 0.3 nM 21.25 27.71 36.31  
18 E2 0.3 nM 21.5 27.94 36.96  
18 E2 0.3 nM 21.02 26.92 37.43  
19 E2 10 nM 21.24 27.05 36.17  
19 E2 10 nM 21.45 27.54 37.13  
19 E2 10 nM 21.73 27.27 36.75  
20 E2 10 nM 21.1 26.45 36.77  
20 E2 10 nM 21.86 26.32 37.01  
20 E2 10 nM 21.24 26.89 37.01  
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6.3.3 PCR Experiment 3  
 
 
 
No. Sample  -Actin ER ER No. Sample  -Actin ER ER 
1 Met 69 pM 23 26.79 36.61 21 E2 10 nM 21.59 26.81 38.13 
1 Met 69 pM 22.99 27.36 36.54 21 E2 10 nM 21.81 26.38 38.53 
1 Met 69 pM 22.79 26.78 37.31 21 E2 10 nM 21.57 24.41 37.67 
2 Met 69 pM 22.85 25 37.45 22 RC 0.36 nM 21.29 25.45 34.85 
2 Met 69 pM 21.99 25.15 36.36 22 RC 0.36 nM 21.64 24.14 35.43 
2 Met 69 pM 21.62 25.98 35.77 22 RC 0.36 nM 21.88 24.96 35.43 
3 Met 69 pM 22.02 25.12 36.85 23 RC 0.36 nM 21.75 24.2 36.67 
3 Met 69 pM 22.4 26.18 37.65 23 RC 0.36 nM 20.97 24.92 36.46 
3 Met 69 pM 22.36 26.26 36.66 23 RC 0.36 nM 21.72 25.73 36.96 
4 Met 0.69 nM 22.05 26.46 38.26 24 RC 0.36 nM 18.96 23.98 33.92 
4 Met 0.69 nM 22.33 26.29 36.9 24 RC 0.36 nM 19.34 24.31 33.83 
4 Met 0.69 nM 21.78 26.43 37.95 24 RC 0.36 nM 19.26 23.9 33.94 
6 Met 0.69 nM 25.3 27.07 40.37 25 RC 36 uM 23.2 27.01 31.13 
6 Met 0.69 nM 23.46 25.55 38.09 25 RC 36 uM 23.23 26.99 31.25 
6 Met 0.69 nM 24.59 25.92 37.42 25 RC 36 uM 22.89 26.1 30.67 
13 Cyper 36uM 22.81 26.03 36.75 26 RC 36 uM 20.03 25.05 35.51 
13 Cyper 36uM 22.06 27.45 36.43 26 RC 36 uM 19.15 24.13 34.84 
13 Cyper 36uM 23.31 26.33 37.26 26 RC 36 uM 19.43 23.75 34.45 
14 Cyper 36uM 20.55 25.19 35.97 27 RC 36 uM 23.49 26.68 33.63 
14 Cyper 36uM 20.43 24.56 35.48 27 RC 36 uM 24.52 27.25 34.14 
14 Cyper 36uM 20.33 25.79 35.16 27 RC 36 uM 22.91 26.11 32.95 
15 Cyper 36uM 21.54 32.07 39.46 28 NTC 20.78 25.5 36.03 
15 Cyper 36uM 21.46 29.74 38.29 28 NTC 20.84 25.67 36.4 
15 Cyper 36uM 21.08 30.09 37.66 28 NTC 21.87 25.08 37.08 
16 E2 0.3 nM 19.86 25.67 35.72 29 NTC 20.77 25.57 36.03 
16 E2 0.3 nM 19.79 24.45 35.76 29 NTC 20.72 25.77 36.59 
16 E2 0.3 nM 20.21 25.3 36.19 30 NTC 21.59 26.53 38.26 
17 E2 0.3 nM 22.24 No Ct 37.29 30 NTC 21.65 26.07 38.51 
17 E2 0.3 nM 21.79 No Ct 37.16 21 NTC 21.59 26.81 38.13 
17 E2 0.3 nM 23.26 44.31 38.49 21 NTC 21.81 26.38 38.53 
18 E2 0.3 nM 20.16 26.45 36.16  
18 E2 0.3 nM 20.69 25.24 37.97  
18 E2 0.3 nM 20.37 26.08 37.1  
19 E2 10 nM 20.82 27 37.56  
19 E2 10 nM 21.44 26 38.81  
19 E2 10 nM 21.08 26.96 38.36  
20 E2 10 nM 20.25 24.34 37.63  
20 E2 10 nM 20.31 24.87 37.54  
20 E2 10 nM 19.92 24.32 38.66  
 
 
 
 
D 
